<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med</journal-id><journal-title-group><journal-title>Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">1749-8546</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4683977</article-id><article-id pub-id-type="pmid">26691584</article-id><article-id pub-id-type="publisher-id">67</article-id><article-id pub-id-type="doi">10.1186/s13020-015-0067-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>In silico target fishing and pharmacological profiling for the isoquinoline alkaloids of <italic>Macleaya</italic><italic>cordata</italic> (<italic>Bo Luo Hui</italic>)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Qifang</given-names></name><address><email>leiqifang66@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Haibo</given-names></name><address><email>hbliu@implad.ac.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Yong</given-names></name><address><email>ypeng@implad.ac.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Peigen</given-names></name><address><email>xiaopg@public.bta.net.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.410318.f</institution-id><institution-id institution-id-type="ISNI">0000000406323409</institution-id><institution>Institute of Medicinal Plant Development, </institution><institution>Chinese Academy of Medical Sciences, </institution></institution-wrap>Beijing, 100193 China </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><elocation-id>37</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Lei et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Some isoquinoline alkaloids from <italic>Macleaya cordata</italic> (Willd). R. Br. (<italic>Bo Luo Hui</italic>) exhibited antibacterial, antiparasitic, antitumor, and analgesic effects. The targets of these isoquinoline alkaloids are undefined. This study aims to investigate the compound&#x02013;target interaction network and potential pharmacological actions of isoquinoline alkaloids of <italic>M. cordata</italic> by reverse pharmacophore database screening.</p></sec><sec><title>Methods</title><p id="Par2">The targets of 26 isoquinoline alkaloids identified from <italic>M. cordata</italic> were predicted by a pharmacophore-based target fishing approach. Discovery Studio 3.5 and two pharmacophore databases (PharmaDB and HypoDB) were employed for the target profiling. A compound&#x02013;target interaction network of <italic>M. cordata</italic> was constructed and analyzed by Cytoscape 3.0.</p></sec><sec><title>Results</title><p id="Par3">Thirteen of the 65 predicted targets identified by PharmaDB were confirmed as targets by HypoDB screening. The targets in the interaction network of <italic>M. cordata</italic> were involved in cancer (31 targets), microorganisms (12 targets), neurodegeneration (10 targets), inflammation and autoimmunity (8 targets), parasitosis (5 targets), injury (4 targets), and pain (3 targets). Dihydrochelerythrine (<bold>C6</bold>) was found to hit 23 fitting targets. Macrophage migration inhibitory factor (MIF) hits 15 alkaloids (<bold>C1</bold>&#x02013;<bold>2</bold>, <bold>C11</bold>&#x02013;<bold>16</bold>, <bold>C19</bold>&#x02013;<bold>25</bold>) was the most promising target related to cancer.</p></sec><sec><title>Conclusion</title><p id="Par4">Through in silico target fishing, the anticancer, anti-inflammatory, and analgesic effects of <italic>M. cordata</italic> were the most significant among many possible activities. The possible anticancer effects were mainly contributed by the isoquinoline alkaloids as active components.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alkaloid</kwd><kwd>Migration Inhibitory Factor</kwd><kwd>Berberine</kwd><kwd>Virtual Screening</kwd><kwd>Mineralocorticoid Receptor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par13">
<italic>Macleaya cordata</italic> (Willd). R. Br. (<italic>Bo Luo Hui</italic>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) has been used for the treatment of cancer [<xref ref-type="bibr" rid="CR1">1</xref>], insect bites [<xref ref-type="bibr" rid="CR2">2</xref>], and ringworm infection [<xref ref-type="bibr" rid="CR3">3</xref>] in Mainland China, North America, and Europe. Phytochemical and pharmacological studies demonstrated that the isoquinoline alkaloids derived from <italic>M. cordata</italic> are its major active components [<xref ref-type="bibr" rid="CR4">4</xref>]. Thirty isoquinoline alkaloids have been isolated from <italic>M. cordata</italic> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), including chelerythrine (<bold>C12</bold>), sanguinarine (<bold>C15</bold>), sanguidimerine (<bold>C17</bold>), chelidimerine (<bold>C18</bold>), berberine (<bold>C21</bold>), coptisine (<bold>C23</bold>), allocryptopine (<bold>C24</bold>, <bold>C25</bold>), and protopine (<bold>C26</bold>). These alkaloids exhibited a broad spectrum of biological activities, such as antitumor [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], anti-inflammatory [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>], antimicrobial [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>], analgesic [<xref ref-type="bibr" rid="CR15">15</xref>], and antioxidant [<xref ref-type="bibr" rid="CR16">16</xref>] activities.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The original plant of <italic>Macleaya cordata</italic>
</p></caption><graphic xlink:href="13020_2015_67_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The isoquinoline alkaloids of <italic>Macleaya cordata</italic>
</p></caption><graphic xlink:href="13020_2015_67_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par14">In our previous study [<xref ref-type="bibr" rid="CR17">17</xref>], we found that <italic>M. cordata</italic> could be counted not only as one of the richest resources in Mainland China among all species of the tribe Chelidonieae, but also as one of the most promising natural resources for drug discovery. <italic>M. cordata</italic> has gained the attention of pharmacognosists since early 1990s (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). However, its obscure molecular actions have hindered its use in drug development.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The statistics of Pubmed publications on <italic>Macleaya cordata</italic> between 1972 and 2014</p></caption><graphic xlink:href="13020_2015_67_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par15">Although protein&#x02013;ligand docking techniques have been available in virtual drug screening for specific targets, such as tumor necrosis factor &#x003b1;-converting enzyme (TACE) [<xref ref-type="bibr" rid="CR18">18</xref>], inducible nitric oxide synthase (iNOS) [<xref ref-type="bibr" rid="CR19">19</xref>], and Janus-activated kinase 2 (JAK2) [<xref ref-type="bibr" rid="CR20">20</xref>], these docking approaches to virtual screening are often too computationally expensive [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par16">This study aims to investigate the compound-target interaction network of isoquinoline alkaloids of <italic>M. cordata</italic> by reverse pharmacophore database screening technology, and outline its potential action mechanisms.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Workflow</title><p id="Par17">Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> shows the workflow of this study. The structures and bioactivities of the isoquinoline alkaloids of <italic>M. cordata</italic> were collected by literature review [<xref ref-type="bibr" rid="CR17">17</xref>]. The alkaloids were then applied to target fishing with two pharmacophore and target databases, PharmaDB and HypoDB. The hit pharmacophore models were picked out according to the threshold of a predetermined fit value. The results from PharmaDB screening were compared with those from HypoDB screening. After analysis of the hit targets and their associated pathways and diseases, as well as the interactions between the alkaloids and the targets, an action network of <italic>M. cordata</italic> was constructed. Literature retrieval was simultaneously carried out to verify the findings.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>The workflow of this study</p></caption><graphic xlink:href="13020_2015_67_Fig4_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec4"><title>Compound collection</title><p id="Par18">The active components of <italic>M. cordata</italic> were collected from our own database [<xref ref-type="bibr" rid="CR17">17</xref>] and the literature. All 26 isoquinoline alkaloids of <italic>M. cordata</italic> and their bioactivities are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, the alkaloids were divided into three classes: benzo<italic>[c]</italic>phenanthridines (Ben, <bold>C1&#x02013;C18</bold>), protoberberines (Ber, <bold>C19&#x02013;C23</bold>), and protopines (Pro, <bold>C24&#x02013;C26</bold>). Based on the replacement of the C-ring, <bold>C1&#x02013;C9</bold> belong to the dihydro-benzo<italic>[c]</italic>phenanthridines, <bold>C10</bold> is a <italic>N</italic>-demethyl 
subtype, and <bold>C11&#x02013;C16</bold> are quaternary ammonium bases that share an iminium moiety (C=N+). The remaining two bisbenzo<italic>[c]</italic>phenanthridines (BisBen, <bold>C17&#x02013;C18</bold>) are epimers to one another.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Basic information of the isoquinoline alkaloids in <italic>M. cordata</italic>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">No.</th><th align="left">Compounds</th><th align="left">Bioactivities</th><th align="left">Virtual hitting targets</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">6-Acetonyl-dihydrosanguinarine</td><td align="left"><p>Anti-bacteria</p><p>Insecticidal</p></td><td align="left">MIF; TTR; NQO1</td></tr><tr><td align="left">2</td><td align="left">6-Acetonyl-dihydrochelerythrine</td><td align="left"><p>Anti-oxidant</p><p>Anti-HIV</p></td><td align="left">HSD1; MIF; PDE4D; NQO1; PLA2s; nAChR 7&#x003b1;; AknH; TtgR</td></tr><tr><td align="left">3</td><td align="left">6-Methoxy-dihydrochelerythrine</td><td align="left"><p>Anti-cancer</p><p>Anti-parasitic</p></td><td align="left">CAR/RXR; MR; ER&#x003b1;; JNK3; SHBG; AR; 15S-LOX; MMP12; PPAR&#x003b3;; SARS M(pro); Scy D; MAO-A</td></tr><tr><td align="left">4</td><td align="left">6-Methoxy-dihydrosanguinarine</td><td align="left"><p>Anti-bacteria</p><p>Anti-cancer</p><p>Anti-platelet aggregation</p></td><td align="left">MR; ER&#x003b1;; FNR; MAO-A</td></tr><tr><td align="left">5</td><td align="left">Bocconoline</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p></td><td align="left">Opsin 2; HSD1; CAR/RXR; MD; ER&#x003b1;; JNK3; SHBG; Chk1; AR; 15S-LOX; CDK2; CAMKII; Aurora A; PIM1; MMP12; Tankyrase 2; SARS M(pro); PfENR; FabZ; DHODH; CDPKs; FNR; ENR; Scy D; MAO-A</td></tr><tr><td align="left">6</td><td align="left">Dihydrochelerythrine</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p></td><td align="left">CAR/RXR; MR; ER&#x003b1;; PPO; TTR; JNK3; SHBG; NQO1; RBP4; 15S-LOX; CK2; PIM1; FabZ; DHODH; SnoaL; FNR; ENR; Scy D; MAO-A; MAO-B; AchE; HIV-1 RT; OSBP</td></tr><tr><td align="left">7</td><td align="left">Dihydrosanguinarine</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p></td><td align="left">MR; ER&#x003b1;; PPO; SHBG; 15S-LOX; CDK2; CK2; MAO-A; AchE</td></tr><tr><td align="left">8</td><td align="left">Oxysanguinarine</td><td align="left">Anti-platelet aggregation</td><td align="left">PIM1; CK2</td></tr><tr><td align="left">9</td><td align="left">Oxychelerythrine</td><td align="left">Cytotoxic</td><td align="left">CAR/RXR; TTR; JNK3; SHBG; 15S-LOX; CLK1; CK2; PIM1; MMP12; MAPK p38; COMP; FabZ; SonaL; FNR; ENR; MAO-A; MAO-B; AchE; OSBP</td></tr><tr><td align="left">10</td><td align="left">Norsanguinarine</td><td align="left">Anti-fungal</td><td align="left">CK2; NmrA</td></tr><tr><td align="left">11</td><td align="left">6-ethoxychelerythrine</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p></td><td align="left">MIF; TTR; JNK3; GAPDH; nAChR 7&#x003b1;; FabZ; CAT; LmrR; HS5B Pol</td></tr><tr><td align="left">12</td><td align="left">Chelerythrine</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p><p>Anti-parasitic</p><p>Anti-cancer</p></td><td align="left">MIF; TTR; FabZ; HS5B Pol</td></tr><tr><td align="left">13</td><td align="left">Chelirubine</td><td align="left">Anti-proliferative</td><td align="left">MIF; NQO1; GR; ZipA-FtsZ; AknH; opdA</td></tr><tr><td align="left">14</td><td align="left">Macarpine</td><td align="left"><p>Cytotoxic</p><p>Anti-proliferative</p></td><td align="left">PDE4B; PDE 4B; MIF; TTR; NQO1; PIM1; MAPK p38; GR; ZipA-FtsZ; AknH</td></tr><tr><td align="left">15</td><td align="left">Sanguinarine</td><td align="left"><p>Anti-bacteria</p><p>Anti-fungal</p><p>Anti-parasitic</p><p>Anti-cancer</p><p>Anti-oxidant</p><p>Hepatotoxicity</p></td><td align="left">MIF; nAChR 7&#x003b1;</td></tr><tr><td align="left">16</td><td align="left">Sanguilutine</td><td align="left">Anti-proliferative</td><td align="left">HSD1; MIF; PDE4D; PLA2s; FabZ</td></tr><tr><td align="left">17</td><td align="left">Sanguidimerine</td><td align="left">Unreported</td><td align="left">ATTP</td></tr><tr><td align="left">18</td><td align="left">Chelidimerine</td><td align="left">Unreported</td><td align="left">MDR HIV-1 Protease</td></tr><tr><td align="left">19</td><td align="left">Chelanthifoline</td><td align="left">Anti-malarial</td><td align="left">ALR; ER&#x003b1;; ER&#x003b2;; MIF; PDK-1; CK2; PIM1; Pi3&#x000a0;K&#x003b3;; GR; nAChR 7&#x003b1;; TEM-1; ActR; MAO-B; HIV-1 RT; OSBP</td></tr><tr><td align="left">20</td><td align="left">Dehydrocicanthifoline</td><td align="left">Unreported</td><td align="left">HSD1; MR; PDE4B; PDE4D; PPO; MIF; TTR; JNK3; CRBP-2; MAPK p38; AR; PIM1; ZipA-FtsZ; HS5B Pol; HIV-1 RT</td></tr><tr><td align="left">21</td><td align="left">Berberine</td><td align="left"><p>Anti-fungal</p><p>Anti-malarial</p><p>Anti-cancer</p><p>Cytotoxic</p><p>Anti-inflammatory</p><p>Anti-Alzheimer&#x02019;s</p><p>Anti-fertility</p><p>Anti-diabetes</p></td><td align="left">MIF; FabZ; Scy D; AchE</td></tr><tr><td align="left">22</td><td align="left">Dehydrochelanthifoline</td><td align="left">Anti-virus</td><td align="left">ER&#x003b1;; ER&#x003b2;; MIF; GSK-3&#x003b2;; TTR; CDK2; PLA2s; MAO-B</td></tr><tr><td align="left">23</td><td align="left">Coptisine</td><td align="left"><p>Cytotoxic</p><p>Anti-diabetes</p><p>CYP2D6 inhibition</p><p>Anti-oxidative</p><p>Anti-spasmodic</p></td><td align="left">MIF</td></tr><tr><td align="left">24</td><td align="left">&#x003b1;-Allocryptopine</td><td align="left"><p>Anti-funga</p><p>Anti-arrhythmic</p></td><td align="left">HSD1; MIF; HS5B Pol; Scy D; BACE1</td></tr><tr><td align="left">25</td><td align="left">&#x003b2;-Allocryptopine</td><td align="left"><p>Anti-parasitic</p><p>Anti-hepatic fibrosis</p></td><td align="left">HSD1; MIF; HS5B POl; Scy D; BACE1; CRALBP; PPO; TTR; nAChR 7&#x003b1;</td></tr><tr><td align="left">26</td><td align="left">Protopine</td><td align="left"><p>Anti-malarial</p><p>Anti-parasitic</p><p>Anti-fertility</p><p>Anti-spasmodic</p></td><td align="left">NQO1; PfENR; TtgR</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec5"><title>Conformation analysis</title><p id="Par19">The structures of all 26 alkaloid candidates were prepared in MOL format, and converted from 2D drawings to 3D models. Their energies were minimized by the software Discovery Studio (DS, v3.5) developed by BIVIA (USA) with the CHARMM force field. A Monte Carlo-based conformational analysis (FAST mode) was performed to generate conformers from the initial conformations. The maximal 255 conformers were allowed with an energy interval of 20&#x000a0;kcal/mol. These alkaloid molecules were rigid, and the number of conformers for each compound was much fewer than 255. Hence, a total of 135 conformers were generated for the 26 isoquinoline alkaloids.</p></sec><sec id="Sec6"><title>Ligand profiling</title><p id="Par20">A pharmacophore model represented a series of common features of a set of ligands with a special pharmacological target. The features of a pharmacophore model reflected the target&#x02013;ligand interaction mode. Pharmacophore-based virtual screening was an alternative to docking. By fitting a compound against a panel of pharmacophore models derived from multiple pharmacological targets, the potential targets of the compound can be outlined.</p><p id="Par21">Automated ligand profiling was available in DS 3.5 as the so-called &#x0201c;Ligand Profiler&#x0201d; protocol. The software offered automated pharmacophore-based activity profiling and reporting [<xref ref-type="bibr" rid="CR22">22</xref>]. In this study, the default parameters of DS 3.5 were used. For each candidate ligand, three or more features were mapped.</p></sec><sec id="Sec7"><title>Pharmacophore databases</title><p id="Par22">DS 3.5 was equipped with two available pharmacophore databases, i.e., HypoDB [<xref ref-type="bibr" rid="CR23">23</xref>] and PharmaDB [<xref ref-type="bibr" rid="CR24">24</xref>]. HypoDB contained about 2500 pharmacophore models derived from protein&#x02013;ligand 3D complex structures as well as structural data on small bioactive organic molecules. PharmaDB was created from the sc-PDB, a well-accepted data source in structure-based profiling protocols. The sc-PDB was a collection of 3D structures of binding sites found in the Protein Data Bank (PDB). The binding sites were extracted from crystal structures in which a complex between a protein cavity and a small molecule ligand could be identified. PharmaDB consisted of about 68,000 pharmacophores derived from 8000 protein&#x02013;ligand complexes from the sc-PDB dataset. PharmaDB is a new and updated pharmacophore database developed in collaboration with Prof. Didier Rognan [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The target and pharmacophore models from PharmaDB and HypoDB were not entirely consistent. PharmaDB had a larger quantity of targets, while the models in the HypoDB were fewer and described as being experimentally validated. Therefore, in this study, PharmaDB was employed in the target fishing, and HypoDB was used to validate the results.</p><p id="Par23">Regarding PharmaDB, multiple pharmacophores with shape or excluded volume constraints were generated for each protein target. For the pharmacophores with shape constraints, the suffix &#x0201c;-s&#x0201d; was added to the name. In addition, a numerical suffix referred to the ranking of selectivity evaluated by a default algorithm in DS v3.5. In this study, only the best models with &#x0201c;&#x02212;1&#x0201d; in their names were employed in the ligand profiling [<xref ref-type="bibr" rid="CR23">23</xref>]. For each pharmacophore database, a classification tree was available, from which the individual models could be selected.</p></sec><sec id="Sec8"><title>Parameters</title><p id="Par24">In the profiling with PharmaDB, all the pharmacophore models with the shape of the binding pocket were selected for the virtual screening with default settings. The RIGID mode was used as the molecular mapping algorithm. No molecular features were allowed to be missed while mapping these ligands to the pharmacophore models to increase selectivity. The minimal inter-feature distance was set at 0.5&#x000a0;&#x000c5;. Parallel screening technology for one or more compounds against a multitude of pharmacophore models was available as a Pipeline Pilot protocol. The number of parallel processing procedures was set at 4. The whole calculation was carried on a T5500 workstation (DELL inc., USA).</p></sec><sec id="Sec9"><title>Binding mode refinement</title><p id="Par25">All the poses of the ligands mapped into the pharmacophore were preserved. A series of target-ligand pairs were selected as emphasis for further examinations. The selection was based upon compatibility with the reported pharmacological activities, as well as traditional usage of <italic>M.</italic>
<italic>cordata</italic>. A further refinement was carried out in Molecular Operating Environment (MOE) developed by CCG (Canada) to identify the protein&#x02013;ligand binding modes. Energy minimization was carried out by conjugated gradient minimization with the MMFF94x force field, until an RMSD of 0.1&#x000a0;kcal&#x000a0;mol<sup>&#x02212;1</sup>&#x000a0;&#x001fa;<sup>&#x02212;1</sup> was reached.</p></sec><sec id="Sec10"><title>Network construction</title><p id="Par26">An interaction table between alkaloids and targets was presented as the ligand profiling results. For each target, the name and pathway information were collected from the PDB and KEGG. The diseases related to the targets were collected from the Therapeutic Target Database (TTD; <ext-link ext-link-type="uri" xlink:href="http://bidd.nus.edu.sg/group/cjttd/">http://bidd.nus.edu.sg/group/cjttd/</ext-link>) [<xref ref-type="bibr" rid="CR27">27</xref>] and DrugBank (<ext-link ext-link-type="uri" xlink:href="http://www.drugbank.ca/">http://www.drugbank.ca/</ext-link>) [<xref ref-type="bibr" rid="CR28">28</xref>] databases. Compound-Target-Pathway networks were generated by Cytoscape 3.0 (Cytoscape Consortium, USA) [<xref ref-type="bibr" rid="CR29">29</xref>]. In the networks, nodes represented the compounds, targets, and biological pathways. The edges linking the compound-target and target-pathway represented their relationships and were marked with different types of lines. After the network was built, the basic parameters of the network were computed and analyzed.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Results and discussion</title><p id="Par27">The profiling results are presented in two HTML tables, designated MoleculeFits and PharmacophoreFits. Two descriptors, fit value and shape similarity, were used to measure the fitness of the ligand and pharmacophore. A fit value equal to or greater than 0.3 was used as a heuristic threshold to select targets from the activity profiler. For each pharmacophore model, the classification information of the target can be indicated in a HTML table created by DS 3.5 called as Pharmacophores. Finally, 98 pharmacophore models were mapped. The models belonged to 65 protein targets, and were involved in 60 pathways. A complete list of the 241 target-ligand pairs is shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The name and indication information of the targets are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The 13 targets verified by HypoDB screening are marked with an asterisk in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>The results of ligand profiling</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Class</th><th align="left">CMD-ID</th><th align="left">ph4</th><th align="left">Target short name</th><th align="left">Gene</th><th align="left">Uniprot-AC</th><th align="left">Fit value</th><th align="left">Shape similarity</th></tr></thead><tbody><tr><td align="left">Ben</td><td char="." align="char">1</td><td align="left">3cfn</td><td align="left">TTR</td><td align="left">TTHY_HUMAN</td><td align="left">P02766</td><td char="." align="char">0.750635</td><td char="." align="char">0.508475</td></tr><tr><td align="left">Ben</td><td char="." align="char">1</td><td align="left">1h69</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.923086</td><td char="." align="char">0.536437</td></tr><tr><td align="left">Ben</td><td char="." align="char">2</td><td align="left">3kba</td><td align="left">Progesterone receptor</td><td align="left">PRGR_HUMAN</td><td align="left">P06401</td><td char="." align="char">0.334698</td><td char="." align="char">0.506897</td></tr><tr><td align="left">Ben</td><td char="." align="char">2</td><td align="left">1xom</td><td align="left">PDE4D</td><td align="left">PDE4D_HUMAN</td><td align="left">Q08499</td><td char="." align="char">0.346437</td><td char="." align="char">0.527574</td></tr><tr><td align="left">Ben</td><td char="." align="char">2</td><td align="left">2wnj</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Q8WSF8_APLCA</td><td align="left">Q8WSF8</td><td char="." align="char">0.43985</td><td char="." align="char">0.505495</td></tr><tr><td align="left">Ben</td><td char="." align="char">2</td><td align="left">1h69</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.928518</td><td char="." align="char">0.504604</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2oz7</td><td align="left">AR</td><td align="left">ANDR_HUMAN</td><td align="left">P10275</td><td char="." align="char">0.360685</td><td char="." align="char">0.500849</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2a3i</td><td align="left">MR</td><td align="left">MCR_HUMAN</td><td align="left">P08235</td><td char="." align="char">0.375601</td><td char="." align="char">0.528195</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.418672</td><td char="." align="char">0.543119</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">1l2i</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.420147</td><td char="." align="char">0.542969</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">1xvp</td><td align="left">CAR/RXR</td><td align="left">NR1I3_HUMAN</td><td align="left">Q14994</td><td char="." align="char">0.460385</td><td char="." align="char">0.534672</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">3lmp</td><td align="left">PPAR&#x003b3;</td><td align="left">PPARG_HUMAN</td><td align="left">P37231</td><td char="." align="char">0.526039</td><td char="." align="char">0.500787</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">1d2s</td><td align="left">SHBG</td><td align="left">SHBG_HUMAN</td><td align="left">P04278</td><td char="." align="char">0.558685</td><td char="." align="char">0.563525</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2gz7</td><td align="left">SARS M(pro)</td><td align="left">R1AB_CVHSA</td><td align="left">P0C6X7</td><td char="." align="char">0.559512</td><td char="." align="char">0.547348</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2p0m</td><td align="left">15S-LOX</td><td align="left">LOX15_RABIT</td><td align="left">P12530</td><td char="." align="char">0.639897</td><td char="." align="char">0.537344</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">3f15</td><td align="left">MMP12</td><td align="left">MMP12_HUMAN</td><td align="left">P39900</td><td char="." align="char">0.725254</td><td char="." align="char">0.50503</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.799156</td><td char="." align="char">0.521008</td></tr><tr><td align="left">Ben</td><td char="." align="char">3</td><td align="left">2o2u</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.835637</td><td char="." align="char">0.577825</td></tr><tr><td align="left">Ben</td><td char="." align="char">4</td><td align="left">2bgi</td><td align="left">FNR</td><td align="left">Q9L6V3_RHOCA</td><td align="left">Q9L6V3</td><td char="." align="char">0.427793</td><td char="." align="char">0.516878</td></tr><tr><td align="left">Ben</td><td char="." align="char">4</td><td align="left">1l2i</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.452535</td><td char="." align="char">0.593291</td></tr><tr><td align="left">Ben</td><td char="." align="char">4</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.793632</td><td char="." align="char">0.533917</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2ol4</td><td align="left">PfENR</td><td align="left">Q9BH77_PLAFA</td><td align="left">Q9BH77</td><td char="." align="char">0.315455</td><td char="." align="char">0.518182</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3g0u</td><td align="left">DHODH</td><td align="left">PYRD_HUMAN</td><td align="left">Q02127</td><td char="." align="char">0.369491</td><td char="." align="char">0.508604</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.387312</td><td char="." align="char">0.544118</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2a3i</td><td align="left">MR</td><td align="left">MCR_HUMAN</td><td align="left">P08235</td><td char="." align="char">0.387489</td><td char="." align="char">0.563771</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">7std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.422146</td><td char="." align="char">0.504744</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2uue</td><td align="left">CDK2</td><td align="left">CDK2_HUMAN</td><td align="left">P24941</td><td char="." align="char">0.424268</td><td char="." align="char">0.567108</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2oz7</td><td align="left">AR</td><td align="left">ANDR_HUMAN</td><td align="left">P10275</td><td char="." align="char">0.426337</td><td char="." align="char">0.510961</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3coh</td><td align="left">Aurora-A</td><td align="left">STK6_HUMAN</td><td align="left">O14965</td><td char="." align="char">0.4511</td><td char="." align="char">0.531532</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3kr8</td><td align="left">Tankyrase 2</td><td align="left">TNKS2_HUMAN</td><td align="left">Q9H2K2</td><td char="." align="char">0.464801</td><td char="." align="char">0.548729</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">1d2s</td><td align="left">SHBG</td><td align="left">SHBG_HUMAN</td><td align="left">P04278</td><td char="." align="char">0.480784</td><td char="." align="char">0.571721</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">1l2i</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.493882</td><td char="." align="char">0.57529</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2wel</td><td align="left">CAMKII</td><td align="left">KCC2D_HUMAN</td><td align="left">Q13557</td><td char="." align="char">0.493929</td><td char="." align="char">0.516729</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3fne</td><td align="left">ENR</td><td align="left">INHA_MYCTU</td><td align="left">P0A5Y6</td><td char="." align="char">0.50498</td><td char="." align="char">0.546169</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">1xvp</td><td align="left">CAR/RXR</td><td align="left">NR1I3_HUMAN</td><td align="left">Q14994</td><td char="." align="char">0.508683</td><td char="." align="char">0.576427</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.522671</td><td char="." align="char">0.566972</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2brg</td><td align="left">Chk1</td><td align="left">CHK1_HUMAN</td><td align="left">O14757</td><td char="." align="char">0.541427</td><td char="." align="char">0.51711</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3doz</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.546379</td><td char="." align="char">0.507843</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2bgi</td><td align="left">FNR</td><td align="left">Q9L6V3_RHOCA</td><td align="left">Q9L6V3</td><td char="." align="char">0.553334</td><td char="." align="char">0.549296</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3fnf</td><td align="left">ENR</td><td align="left">INHA_MYCTU</td><td align="left">P0A5Y6</td><td char="." align="char">0.562321</td><td char="." align="char">0.511494</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3fnh</td><td align="left">ENR</td><td align="left">INHA_MYCTU</td><td align="left">P0A5Y6</td><td char="." align="char">0.614823</td><td char="." align="char">0.507547</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2p0m</td><td align="left">15S-LOX</td><td align="left">LOX15_RABIT</td><td align="left">P12530</td><td char="." align="char">0.673148</td><td char="." align="char">0.541414</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3dp1</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.687924</td><td char="." align="char">0.53816</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2gz7</td><td align="left">SARS M(pro)</td><td align="left">R1AB_CVHSA</td><td align="left">P0C6X7</td><td char="." align="char">0.694125</td><td char="." align="char">0.551789</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">2o2u</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.805153</td><td char="." align="char">0.553719</td></tr><tr><td align="left">Ben</td><td char="." align="char">5</td><td align="left">3f15</td><td align="left">MMP12</td><td align="left">MMP12_HUMAN</td><td align="left">P39900</td><td char="." align="char">0.893862</td><td char="." align="char">0.507187</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">3fj6</td><td align="left">DHODH</td><td align="left">PYRD_HUMAN</td><td align="left">Q02127</td><td char="." align="char">0.341464</td><td char="." align="char">0.566038</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.364451</td><td char="." align="char">0.555556</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1d2s</td><td align="left">SHBG</td><td align="left">SHBG_HUMAN</td><td align="left">P04278</td><td char="." align="char">0.367805</td><td char="." align="char">0.529289</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2a3i</td><td align="left">MR</td><td align="left">MCR_HUMAN</td><td align="left">P08235</td><td char="." align="char">0.368001</td><td char="." align="char">0.559289</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1xvp</td><td align="left">CAR/RXR</td><td align="left">NR1I3_HUMAN</td><td align="left">Q14994</td><td char="." align="char">0.423023</td><td char="." align="char">0.572534</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2v60</td><td align="left">MAO-B</td><td align="left">AOFB_HUMAN</td><td align="left">P27338</td><td char="." align="char">0.436774</td><td char="." align="char">0.511294</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1l2i</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.451108</td><td char="." align="char">0.529175</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1rbp</td><td align="left">RBP4</td><td align="left">RET4_HUMAN</td><td align="left">P02753</td><td char="." align="char">0.486949</td><td char="." align="char">0.516378</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2nsd</td><td align="left">ENR</td><td align="left">INHA_MYCTU</td><td align="left">P0A5Y6</td><td char="." align="char">0.509088</td><td char="." align="char">0.530738</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1kgj</td><td align="left">TTR</td><td align="left">TTHY_RAT</td><td align="left">P02767</td><td char="." align="char">0.522255</td><td char="." align="char">0.529412</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1tv6</td><td align="left">HIV-1 TR</td><td align="left">POL_HV1B1</td><td align="left">P03366</td><td char="." align="char">0.564494</td><td char="." align="char">0.529981</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2bgi</td><td align="left">FNR</td><td align="left">Q9L6V3_RHOCA</td><td align="left">Q9L6V3</td><td char="." align="char">0.636419</td><td char="." align="char">0.536325</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2p0m</td><td align="left">15S-LOX</td><td align="left">LOX15_RABIT</td><td align="left">P12530</td><td char="." align="char">0.663082</td><td char="." align="char">0.545045</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">3imu</td><td align="left">TTR</td><td align="left">TTHY_HUMAN</td><td align="left">P02766</td><td char="." align="char">0.690803</td><td char="." align="char">0.577011</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">3dp1</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.705916</td><td char="." align="char">0.565401</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2o2u</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.705945</td><td char="." align="char">0.507463</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1h69</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.755827</td><td char="." align="char">0.508911</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.795152</td><td char="." align="char">0.541573</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">1sjw</td><td align="left">SnoaL</td><td align="left">Q9RN59_STRNO</td><td align="left">Q9RN59</td><td char="." align="char">0.904111</td><td char="." align="char">0.661572</td></tr><tr><td align="left">Ben</td><td char="." align="char">6</td><td align="left">2j3q</td><td align="left">AChE</td><td align="left">ACES_TORCA</td><td align="left">P04058</td><td char="." align="char">0.992134</td><td char="." align="char">0.661327</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">2x1n</td><td align="left">CDK2</td><td align="left">CDK2_HUMAN</td><td align="left">P24941</td><td char="." align="char">0.329358</td><td char="." align="char">0.521253</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">1d2s</td><td align="left">SHBG</td><td align="left">SHBG_HUMAN</td><td align="left">P04278</td><td char="." align="char">0.340019</td><td char="." align="char">0.542857</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">1l2i</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.465563</td><td char="." align="char">0.553846</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">2j3q</td><td align="left">AChE</td><td align="left">ACES_TORCA</td><td align="left">P04058</td><td char="." align="char">0.470546</td><td char="." align="char">0.67</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">2p0m</td><td align="left">15S-LOX</td><td align="left">LOX15_RABIT</td><td align="left">P12530</td><td char="." align="char">0.639874</td><td char="." align="char">0.545254</td></tr><tr><td align="left">Ben</td><td char="." align="char">7</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.822509</td><td char="." align="char">0.548694</td></tr><tr><td align="left">Ben</td><td char="." align="char">8</td><td align="left">3bgp</td><td align="left">PIM-1</td><td align="left">PIM1_HUMAN</td><td align="left">P11309</td><td char="." align="char">0.659102</td><td char="." align="char">0.52193</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2wu7</td><td align="left">CLK1</td><td align="left">CLK3_HUMAN</td><td align="left">P49761</td><td char="." align="char">0.333353</td><td char="." align="char">0.541053</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">1d2s</td><td align="left">SHBG</td><td align="left">SHBG_HUMAN</td><td align="left">P04278</td><td char="." align="char">0.40988</td><td char="." align="char">0.526096</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2nsd</td><td align="left">ENR</td><td align="left">INHA_MYCTU</td><td align="left">P0A5Y6</td><td char="." align="char">0.417703</td><td char="." align="char">0.522727</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">1tha</td><td align="left">TTR</td><td align="left">TTHY_HUMAN</td><td align="left">P02766</td><td char="." align="char">0.42188</td><td char="." align="char">0.505071</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">1xvp</td><td align="left">CAR/RXR</td><td align="left">NR1I3_HUMAN</td><td align="left">Q14994</td><td char="." align="char">0.459386</td><td char="." align="char">0.600775</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">1fbm</td><td align="left">COMP</td><td align="left">COMP_RAT</td><td align="left">P35444</td><td char="." align="char">0.540756</td><td char="." align="char">0.509542</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2p0m</td><td align="left">15S-LOX</td><td align="left">LOX15_RABIT</td><td align="left">P12530</td><td char="." align="char">0.609094</td><td char="." align="char">0.548596</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2bxr</td><td align="left">MAO-A</td><td align="left">AOFA_HUMAN</td><td align="left">P21397</td><td char="." align="char">0.636415</td><td char="." align="char">0.524336</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">3iw7</td><td align="left">MAPK p38</td><td align="left">MK14_HUMAN</td><td align="left">Q16539</td><td char="." align="char">0.671331</td><td char="." align="char">0.532803</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">1sjw</td><td align="left">SnoaL</td><td align="left">Q9RN59_STRNO</td><td align="left">Q9RN59</td><td char="." align="char">0.679871</td><td char="." align="char">0.665953</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2bgi</td><td align="left">FNR</td><td align="left">Q9L6V3_RHOCA</td><td align="left">Q9L6V3</td><td char="." align="char">0.68446</td><td char="." align="char">0.509554</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">3dp1</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.723083</td><td char="." align="char">0.601732</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2v60</td><td align="left">MAO-B</td><td align="left">AOFB_HUMAN</td><td align="left">P27338</td><td char="." align="char">0.818911</td><td char="." align="char">0.501006</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2o2u</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.878824</td><td char="." align="char">0.532609</td></tr><tr><td align="left">Ben</td><td char="." align="char">9</td><td align="left">2j3q</td><td align="left">AChE</td><td align="left">ACES_TORCA</td><td align="left">P04058</td><td char="." align="char">0.992667</td><td char="." align="char">0.679157</td></tr><tr><td align="left">Ben</td><td char="." align="char">10</td><td align="left">2wmd</td><td align="left">NmrA</td><td align="left">NMRL1_HUMAN</td><td align="left">Q9HBL8</td><td char="." align="char">0.635677</td><td char="." align="char">0.601671</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">3doz</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.380298</td><td char="." align="char">0.514677</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">3kvx</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.408174</td><td char="." align="char">0.518987</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">2wnj</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Q8WSF8_APLCA</td><td align="left">Q8WSF8</td><td char="." align="char">0.408648</td><td char="." align="char">0.512476</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">3doy</td><td align="left">FabZ</td><td align="left">Q5G940_HELPY</td><td align="left">Q5G940</td><td char="." align="char">0.456816</td><td char="." align="char">0.515444</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">1k3t</td><td align="left">GAPDH</td><td align="left">G3PG_TRYCR</td><td align="left">P22513</td><td char="." align="char">0.56209</td><td char="." align="char">0.500931</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">3lmp</td><td align="left">PPAR&#x003b3;</td><td align="left">PPARG_HUMAN</td><td align="left">P37231</td><td char="." align="char">0.648243</td><td char="." align="char">0.508527</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">1qca</td><td align="left">CAT</td><td align="left">CAT3_ECOLX</td><td align="left">P00484</td><td char="." align="char">0.780585</td><td char="." align="char">0.505747</td></tr><tr><td align="left">Ben</td><td char="." align="char">11</td><td align="left">3f8f</td><td align="left">LmrR</td><td align="left">A2RI36_LACLM</td><td align="left">A2RI36</td><td char="." align="char">0.817481</td><td char="." align="char">0.51932</td></tr><tr><td align="left">Ben</td><td char="." align="char">13</td><td align="left">1xan</td><td align="left">GR</td><td align="left">GSHR_HUMAN</td><td align="left">P00390</td><td char="." align="char">0.573697</td><td char="." align="char">0.520833</td></tr><tr><td align="left">Ben</td><td char="." align="char">13</td><td align="left">3kba</td><td align="left">Progesterone receptor</td><td align="left">PRGR_HUMAN</td><td align="left">P06401</td><td char="." align="char">0.651629</td><td char="." align="char">0.522059</td></tr><tr><td align="left">Ben</td><td char="." align="char">13</td><td align="left">1h69</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.811055</td><td char="." align="char">0.503055</td></tr><tr><td align="left">Ben</td><td char="." align="char">13</td><td align="left">3a3w</td><td align="left">opdA</td><td align="left">Q93LD7_RHIRD</td><td align="left">Q93LD7</td><td char="." align="char">0.833715</td><td char="." align="char">0.510158</td></tr><tr><td align="left">Ben</td><td char="." align="char">14</td><td align="left">3huc</td><td align="left">MAPK p38</td><td align="left">MK14_HUMAN</td><td align="left">Q16539</td><td char="." align="char">0.345074</td><td char="." align="char">0.534091</td></tr><tr><td align="left">Ben</td><td char="." align="char">14</td><td align="left">1xan</td><td align="left">GR</td><td align="left">GSHR_HUMAN</td><td align="left">P00390</td><td char="." align="char">0.517848</td><td char="." align="char">0.510823</td></tr><tr><td align="left">Ben</td><td char="." align="char">14</td><td align="left">1h69</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.723867</td><td char="." align="char">0.515504</td></tr><tr><td align="left">Ben</td><td char="." align="char">14</td><td align="left">1xom</td><td align="left">PDE4D</td><td align="left">PDE4D_HUMAN</td><td align="left">Q08499</td><td char="." align="char">0.745933</td><td char="." align="char">0.503704</td></tr><tr><td align="left">Ben</td><td char="." align="char">14</td><td align="left">1xlx</td><td align="left">PDE4B</td><td align="left">PDE4B_HUMAN</td><td align="left">Q07343</td><td char="." align="char">0.796555</td><td char="." align="char">0.52037</td></tr><tr><td align="left">Ben</td><td char="." align="char">15</td><td align="left">2wnj</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Q8WSF8_APLCA</td><td align="left">Q8WSF8</td><td char="." align="char">0.495424</td><td char="." align="char">0.509356</td></tr><tr><td align="left">Ben</td><td char="." align="char">16</td><td align="left">3kba</td><td align="left">Progesterone receptor</td><td align="left">PRGR_HUMAN</td><td align="left">P06401</td><td char="." align="char">0.342606</td><td char="." align="char">0.537671</td></tr><tr><td align="left">Ben</td><td char="." align="char">16</td><td align="left">1xom</td><td align="left">PDE4D</td><td align="left">PDE4D_HUMAN</td><td align="left">Q08499</td><td char="." align="char">0.816692</td><td char="." align="char">0.539427</td></tr><tr><td align="left">BisBen</td><td char="." align="char">17</td><td align="left">1r5&#x000a0;l</td><td align="left">ATTP</td><td align="left">TTPA_HUMAN</td><td align="left">P49638</td><td char="." align="char">0.32356</td><td char="." align="char">0.514156</td></tr><tr><td align="left">BisBen</td><td char="." align="char">18</td><td align="left">1rq9</td><td align="left">MDR HIV-1 Protease</td><td align="left">Q5RTL1_9HIV</td><td align="left">Q5RTL1</td><td char="." align="char">0.621229</td><td char="." align="char">0.507743</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1u3s</td><td align="left">ER&#x003b2;</td><td align="left">ESR2_HUMAN</td><td align="left">Q92731</td><td char="." align="char">0.408794</td><td char="." align="char">0.535377</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">2j3q</td><td align="left">AChE</td><td align="left">ACES_TORCA</td><td align="left">P04058</td><td char="." align="char">0.485705</td><td char="." align="char">0.596737</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">3l54</td><td align="left">Pi3&#x000a0;K&#x003b3;</td><td align="left">PK3CG_HUMAN</td><td align="left">P48736</td><td char="." align="char">0.498919</td><td char="." align="char">0.59589</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1pzo</td><td align="left">TEM-1</td><td align="left">BLAT_ECOLX</td><td align="left">P62593</td><td char="." align="char">0.523404</td><td char="." align="char">0.526667</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">2ikg</td><td align="left">ALR</td><td align="left">ALDR_HUMAN</td><td align="left">P15121</td><td char="." align="char">0.561704</td><td char="." align="char">0.507109</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1c1c</td><td align="left">HIV-1 TR</td><td align="left">POL_HV1H2</td><td align="left">P04585</td><td char="." align="char">0.577074</td><td char="." align="char">0.542373</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">2r7b</td><td align="left">PDK-1</td><td align="left">PDPK1_HUMAN</td><td align="left">O15530</td><td char="." align="char">0.587223</td><td char="." align="char">0.533049</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1yye</td><td align="left">ER&#x003b2;</td><td align="left">ESR2_HUMAN</td><td align="left">Q92731</td><td char="." align="char">0.679767</td><td char="." align="char">0.56691</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1qkt</td><td align="left">ER&#x003b1;</td><td align="left">ESR1_HUMAN</td><td align="left">P03372</td><td char="." align="char">0.681913</td><td char="." align="char">0.56351</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1xan</td><td align="left">GR</td><td align="left">GSHR_HUMAN</td><td align="left">P00390</td><td char="." align="char">0.715506</td><td char="." align="char">0.548544</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">2wnj</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Q8WSF8_APLCA</td><td align="left">Q8WSF8</td><td char="." align="char">0.87937</td><td char="." align="char">0.501031</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">3b6c</td><td align="left">ActR</td><td align="left">Q53901_STRCO</td><td align="left">Q53901</td><td char="." align="char">0.880577</td><td char="." align="char">0.597561</td></tr><tr><td align="left">Ber</td><td char="." align="char">19</td><td align="left">1x78</td><td align="left">ER&#x003b2;</td><td align="left">ESR2_HUMAN</td><td align="left">Q92731</td><td char="." align="char">0.909059</td><td char="." align="char">0.522565</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1xm4</td><td align="left">PDE4B</td><td align="left">PDE4B_HUMAN</td><td align="left">Q07343</td><td char="." align="char">0.402388</td><td char="." align="char">0.569138</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1tha</td><td align="left">TTR</td><td align="left">TTHY_HUMAN</td><td align="left">P02766</td><td char="." align="char">0.45615</td><td char="." align="char">0.514286</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1tv6</td><td align="left">HIV-1 TR</td><td align="left">POL_HV1B1</td><td align="left">P03366</td><td char="." align="char">0.459002</td><td char="." align="char">0.521154</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">2nw4</td><td align="left">AR</td><td align="left">ANDR_RAT</td><td align="left">P15207</td><td char="." align="char">0.463505</td><td char="." align="char">0.541203</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1opb</td><td align="left">CRBP2</td><td align="left">RET2_RAT</td><td align="left">P06768</td><td char="." align="char">0.485837</td><td char="." align="char">0.534653</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">2waj</td><td align="left">JNK3</td><td align="left">MK10_HUMAN</td><td align="left">P53779</td><td char="." align="char">0.572085</td><td char="." align="char">0.603104</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1kgj</td><td align="left">TTR</td><td align="left">TTHY_RAT</td><td align="left">P02767</td><td char="." align="char">0.740087</td><td char="." align="char">0.56531</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1xom</td><td align="left">PDE4D</td><td align="left">PDE4D_HUMAN</td><td align="left">Q08499</td><td char="." align="char">0.811727</td><td char="." align="char">0.542406</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">1xlx</td><td align="left">PDE4B</td><td align="left">PDE4B_HUMAN</td><td align="left">Q07343</td><td char="." align="char">0.859016</td><td char="." align="char">0.51341</td></tr><tr><td align="left">Ber</td><td char="." align="char">20</td><td align="left">3i6d</td><td align="left">PPO</td><td align="left">PPOX_BACSU</td><td align="left">P32397</td><td char="." align="char">0.97618</td><td char="." align="char">0.570499</td></tr><tr><td align="left">Ber</td><td char="." align="char">21</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.324086</td><td char="." align="char">0.505682</td></tr><tr><td align="left">Ber</td><td char="." align="char">21</td><td align="left">2j3q</td><td align="left">AChE</td><td align="left">ACES_TORCA</td><td align="left">P04058</td><td char="." align="char">0.992907</td><td char="." align="char">0.672209</td></tr><tr><td align="left">Ber</td><td char="." align="char">22</td><td align="left">1di8</td><td align="left">CDK2</td><td align="left">CDK2_HUMAN</td><td align="left">P24941</td><td char="." align="char">0.406566</td><td char="." align="char">0.501094</td></tr><tr><td align="left">Ber</td><td char="." align="char">22</td><td align="left">1u3s</td><td align="left">ER&#x003b2;</td><td align="left">ESR2_HUMAN</td><td align="left">Q92731</td><td char="." align="char">0.661777</td><td char="." align="char">0.509434</td></tr><tr><td align="left">Pro</td><td char="." align="char">24</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.538905</td><td char="." align="char">0.543636</td></tr><tr><td align="left">Pro</td><td char="." align="char">24</td><td align="left">3ine</td><td align="left">BACE1</td><td align="left">BACE1_HUMAN</td><td align="left">P56817</td><td char="." align="char">0.54561</td><td char="." align="char">0.522968</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">1tyr</td><td align="left">TTR</td><td align="left">TTHY_HUMAN</td><td align="left">P02766</td><td char="." align="char">0.356425</td><td char="." align="char">0.526412</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">3inf</td><td align="left">BACE1</td><td align="left">BACE1_HUMAN</td><td align="left">P56817</td><td char="." align="char">0.37118</td><td char="." align="char">0.504303</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">2wnj</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Q8WSF8_APLCA</td><td align="left">Q8WSF8</td><td char="." align="char">0.553029</td><td char="." align="char">0.533461</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">3ine</td><td align="left">BACE1</td><td align="left">BACE1_HUMAN</td><td align="left">P56817</td><td char="." align="char">0.597712</td><td char="." align="char">0.51259</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">3hx3</td><td align="left">CRALBP</td><td align="left">RLBP1_HUMAN</td><td align="left">P12271</td><td char="." align="char">0.604625</td><td char="." align="char">0.513158</td></tr><tr><td align="left">Pro</td><td char="." align="char">25</td><td align="left">5std</td><td align="left">ScyD</td><td align="left">SCYD_MAGGR</td><td align="left">P56221</td><td char="." align="char">0.763034</td><td char="." align="char">0.522523</td></tr><tr><td align="left">Pro</td><td char="." align="char">26</td><td align="left">2ow2</td><td align="left">PfENR</td><td align="left">MMP9_HUMAN</td><td align="left">P14780</td><td char="." align="char">0.302479</td><td char="." align="char">0.507865</td></tr><tr><td align="left">Pro</td><td char="." align="char">26</td><td align="left">2f1o</td><td align="left">NQO1</td><td align="left">NQO1_HUMAN</td><td align="left">P15559</td><td char="." align="char">0.432407</td><td char="." align="char">0.52183</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>The targets identified</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Targets</th><th align="left">Short name</th><th align="left">Type</th><th align="left">Pathway</th><th align="left">Diseases</th></tr></thead><tbody><tr><td align="left">Retinaldehyde-binding protein</td><td align="left">CRALBP</td><td align="left">Research</td><td align="left">Retinaldehyde metabolism</td><td align="left">Retinitis pigmentosa</td></tr><tr><td align="left">Rhodopsin</td><td align="left">Opsin 2</td><td align="left">Research</td><td align="left">Retina metabolism</td><td align="left">Retinitis pigmentosa</td></tr><tr><td align="left">11-Beta-hydroxysteroid dehydrogenase</td><td align="left">HSD1</td><td align="left">Successful</td><td align="left">Glucocorticoid concentration</td><td align="left"><p>Diabetes</p><p>Osteoporosis</p><p>Hepatotoxicity</p></td></tr><tr><td align="left">CAR/RXR heterodimer</td><td align="left">CAR/RXR</td><td align="left">Research</td><td align="left">Triglyceride metabolism</td><td align="left"><p>Diabetes</p><p>Hepatitis</p></td></tr><tr><td align="left">Aldose reductase</td><td align="left">ALR</td><td align="left">Successful</td><td align="left">Glucolipid metabolism</td><td align="left"><p>Diabetes</p><p>Pain</p></td></tr><tr><td align="left">Mineralocorticoid receptors</td><td align="left">MR</td><td align="left">Successful</td><td align="left">Na<sup>+</sup>/K<sup>+</sup> equilibrium</td><td align="left"><p>Inflammatory, autoimmune disease</p><p>Injury</p></td></tr><tr><td align="left">Phosphodiesterase 4B</td><td align="left">PDE4B</td><td align="left">Successful</td><td align="left">AKT/mTOR pathway</td><td align="left"><p>Cancer</p><p>Obesity</p></td></tr><tr><td align="left">Phosphodiesterase 4D</td><td align="left">PDE4D</td><td align="left">Successful</td><td align="left">Intracellular cAMP//CREB signaling</td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p></td></tr><tr><td align="left">Protoporphyrinogen oxidase</td><td align="left">PPO</td><td align="left">Research</td><td align="left">Heme biosynthesis</td><td align="left"><p>Cancer</p><p>Parasitosis</p></td></tr><tr><td align="left">Transthyretin</td><td align="left">TTR</td><td align="left">Clinic Trial</td><td align="left">Thyroxine carrier</td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p></td></tr><tr><td align="left">Mitogen-activated protein kinase 10</td><td align="left">JNK3</td><td align="left">Research</td><td align="left">GbRH/ErbB/MAPK/insulin signaling pathway</td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p></td></tr><tr><td align="left">Sex hormone-binding globulin</td><td align="left">SHBG</td><td align="left">Research</td><td align="left">Sex steroids biosynthesis</td><td align="left">Cancer</td></tr><tr><td align="left">NAD(P)H:quinone oxidoreductase</td><td align="left">NQO1</td><td align="left">Research</td><td align="left">Quinones metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">Cellular retinol binding protein II</td><td align="left">CRBP2</td><td align="left">Research</td><td align="left">Retinol metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">Estrogen receptor alpha<sup>a</sup>
</td><td align="left">ER&#x003b1;<sup>a</sup>
</td><td align="left">Successful</td><td align="left"><p>Estrogen metabolism</p><p>Insulin-like growth factor pathway</p></td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p><p>Injury</p><p>Osteoporosis</p></td></tr><tr><td align="left">Alpha-tocopherol (alpha-T) transfer protein</td><td align="left">ATTP</td><td align="left">Research</td><td align="left">&#x003b1;-Tocopherol metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">Human serum retinol binding protein 4</td><td align="left">RBP4</td><td align="left">Research</td><td align="left">Retinol metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">Estrogen receptor beta<sup>a</sup>
</td><td align="left">ER&#x003b2;<sup>a</sup>
</td><td align="left">Successful</td><td align="left"><p>Estrogen metabolism</p><p>MAPK, PI3K signaling</p></td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p><p>Injury</p></td></tr><tr><td align="left">Checkpoint kinase 1<sup>a</sup>
</td><td align="left">Chk1<sup>a</sup>
</td><td align="left">Research</td><td align="left">DNA damage response</td><td align="left">Cancer</td></tr><tr><td align="left">Androgen receptor</td><td align="left">AR</td><td align="left">Successful</td><td align="left">Hormone metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">Reticulocyte 15S-lipoxygenase</td><td align="left">15S-LOX</td><td align="left">Research</td><td align="left">Arachidonic acid metabolism</td><td align="left">Cancer</td></tr><tr><td align="left">3-Phosphoinositide-dependent kinase-1<sup>a</sup>
</td><td align="left">PDK-1<sup>a</sup>
</td><td align="left">Research</td><td align="left">Phosphatidylinositol 3 kinase (PI3K) signaling</td><td align="left">Cancer</td></tr><tr><td align="left">Casein kinase 2<sup>a</sup>
</td><td align="left">CK2<sup>a</sup>
</td><td align="left">Research</td><td align="left">Ser/Thr pathway</td><td align="left">Cancer</td></tr><tr><td align="left">Cyclin dependent kinase 2<sup>a</sup>
</td><td align="left">CDK2<sup>a</sup>
</td><td align="left">Research</td><td align="left">Cell cycle</td><td align="left">Cancer</td></tr><tr><td align="left">Calcium/calmodulin dependent protein kinase II delta</td><td align="left">CAMKII</td><td align="left">Research</td><td align="left"><p>NF-&#x003ba;B-mediated inflammatory response</p><p>Ca<sup>2+</sup>-linked signaling</p></td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p></td></tr><tr><td align="left">Dual-specificity protein kinase 1</td><td align="left">CLK1</td><td align="left">Research</td><td align="left">Nuclear redistribution of SR proteins</td><td align="left">Cancer</td></tr><tr><td align="left">Proto-oncogene serine threonine kinase<sup>a</sup>
</td><td align="left">PIM-1<sup>a</sup>
</td><td align="left">Research</td><td align="left">Cell cycle regulation JAK/STAT pathway</td><td align="left">Cancer</td></tr><tr><td align="left">Aurora kinase A</td><td align="left">Aurora-A</td><td align="left">Clinical trial</td><td align="left">Cell cycle arrest</td><td align="left">Cancer</td></tr><tr><td align="left">Matrix metalloproteinases</td><td align="left">MMP12</td><td align="left">Research</td><td align="left">Cell invasion, metastasis</td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p></td></tr><tr><td align="left">Phospholipase A2</td><td align="left">PLA2s</td><td align="left">Successful</td><td align="left">VEGF/MAPK/GnRH signaling</td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p></td></tr><tr><td align="left">Mitogen-Activated Protein Kinases p38</td><td align="left">MAPK p38</td><td align="left">Clinical trial</td><td align="left">MAPK signaling</td><td align="left"><p>Cancer</p><p>Pain</p><p>Inflammatory, autoimmune disease</p><p>Dermatosis</p></td></tr><tr><td align="left">Tankyrase 2</td><td align="left">Tankyrase 2</td><td align="left">Research</td><td align="left">Canonical Wnt signaling</td><td align="left">Cancer</td></tr><tr><td align="left">Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform</td><td align="left">Pi3K&#x003b3;</td><td align="left">Research</td><td align="left"><p>Cancer migration, invasion</p><p>Inositol phosphate metabolism</p></td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p></td></tr><tr><td align="left">PPARgamma-LBD<sup>a</sup>
</td><td align="left">PPAR&#x003b3;<sup>a</sup>
</td><td align="left">Research</td><td align="left">LPS-induced iNOS expression</td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p><p>Osteoporosis</p></td></tr><tr><td align="left">Cartilage oligomeric matrix protein</td><td align="left">COMP</td><td align="left">Research</td><td align="left">Bone regeneration</td><td align="left"><p>Autoimmune disease</p><p>Injury</p></td></tr><tr><td align="left">Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (M(pro))</td><td align="left">SARS M(pro)</td><td align="left">Research</td><td align="left">Virus maturation</td><td align="left">Virus infection</td></tr><tr><td align="left">Glycosomal glyceraldehyde-3-Phosphate Dehydrogenase</td><td align="left">GAPDH</td><td align="left">Successful</td><td align="left">Glyceraldehydes metabolism</td><td align="left">Parasitosis</td></tr><tr><td align="left">Glutathione disulfide oxidoreductase</td><td align="left">GR</td><td align="left">Research</td><td align="left">Glutathione metabolism</td><td align="left">Parasitosis</td></tr><tr><td align="left">Acyl carrier protein reductase<sup>a</sup>
</td><td align="left">PfENR<sup>a</sup>
</td><td align="left">Successful</td><td align="left">Fatty acid biosynthesis</td><td align="left">Parasitosis</td></tr><tr><td align="left">Acetylcholine binding protein alpha7</td><td align="left">nAChR 7&#x003b1;</td><td align="left">Successful</td><td align="left">Calcium signaling pathway</td><td align="left"><p>Alzheimer&#x02019;s</p><p>Pain</p></td></tr><tr><td align="left">3R-hydroxyacyl-acyl carrier protein dehydratase</td><td align="left">FabZ</td><td align="left">Research</td><td align="left">Fatty acid biosynthesis</td><td align="left">Parasitosis</td></tr><tr><td align="left">Dihydroorotate dehydrogenase</td><td align="left">DHODH</td><td align="left">Successful</td><td align="left">Pyrimidine metabolism</td><td align="left">Parasitosis</td></tr><tr><td align="left">TEM-1 Beta-Lactamase<sup>a</sup>
</td><td align="left">TEM-1<sup>a</sup>
</td><td align="left">Successful</td><td align="left">Cefotaxime metabolism</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Chloramphenicol acetyltransferase</td><td align="left">CAT</td><td align="left">Research</td><td align="left">Chloramphenicol metabolism</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Polyketide cyclase SnoaL</td><td align="left">SnoaL</td><td align="left">Research</td><td align="left">Nogalamycin biosynthesis</td><td align="left">Bacterial infection</td></tr><tr><td align="left">ZipA attaches FtsZ protein</td><td align="left">ZipA-FtsZ</td><td align="left">Research</td><td align="left">Cell division</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Ferredoxin-NADP<sup>+</sup> reductase</td><td align="left">FNR</td><td align="left">Successful</td><td align="left">Redox metabolism</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Polyketide cyclase AknH</td><td align="left">AknH</td><td align="left">Research</td><td align="left">Aclacinomycin biosynthesis</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Enoyl-acyl carrier protein reductase</td><td align="left">ENR</td><td align="left">Successful</td><td align="left">Fatty acid biosynthesis</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Multidrug binding protein TtgR</td><td align="left">TtgR</td><td align="left">Research</td><td align="left">Active extrusion of drug</td><td align="left">Bacterial infection</td></tr><tr><td align="left">NmrA-like family domain</td><td align="left">NmrA</td><td align="left">Research</td><td align="left">Transcriptional repress</td><td align="left">Fungal infection</td></tr><tr><td align="left">Bacterial phosphotriesterase</td><td align="left">opdA</td><td align="left">Research</td><td align="left">Organophosphate metabolism</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Streptomyces coelicolor TetR family protein ActR<sup>a</sup>
</td><td align="left">ActR<sup>a</sup>
</td><td align="left">Research</td><td align="left">Transcriptional repress</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Multidrug binding transcriptional regulator LmrR</td><td align="left">LmrR</td><td align="left">Research</td><td align="left">Autoregulatory mechanism</td><td align="left">Bacterial infection</td></tr><tr><td align="left">Scytalone Dehydratase</td><td align="left">ScyD</td><td align="left">Research</td><td align="left">Fungicide</td><td align="left">Fungal infection</td></tr><tr><td align="left">Human monoamine oxidase A</td><td align="left">MAO-A</td><td align="left">Successful</td><td align="left">Monoamines metabolism</td><td align="left">Depression</td></tr><tr><td align="left">Acetylcholin esterase</td><td align="left">AChE</td><td align="left">Successful</td><td align="left">Glycerophospholipid metabolism</td><td align="left"><p>Alzheimer&#x02019;s</p><p>Parkinson&#x02019;s</p></td></tr><tr><td align="left">&#x003b2;-Site amyloid precursor protein cleaving enzyme</td><td align="left">BACE1</td><td align="left">Clinical trial</td><td align="left">Neuregulin processing</td><td align="left">Alzheimer&#x02019;s</td></tr><tr><td align="left">Multidrug-resistant HIV-1 protease<sup>a</sup>
</td><td align="left">MDR HIV-1 protease<sup>a</sup>
</td><td align="left">Successful</td><td align="left">Self-activation</td><td align="left">AIDs</td></tr><tr><td align="left">HIV-1 reverse transcriptase</td><td align="left">HIV-1 TR</td><td align="left">Successful</td><td align="left">ATP-dependent excision, pyrophosphorolysis</td><td align="left">AIDs</td></tr><tr><td align="left">Oxysterol binding protein</td><td align="left">OSBP</td><td align="left">Research</td><td align="left"><p>Intracellular lipid homeostasis</p><p>Signal conduction</p></td><td align="left"><p>Virus infection</p><p>Cancer</p></td></tr><tr><td align="left">Rhodopsin</td><td align="left">Opsin 2</td><td align="left">Research</td><td align="left">Rod photoreceptor</td><td align="left">Retinitis pigmentosa</td></tr><tr><td align="left">Macrophage migration inhibitory factor</td><td align="left">MIF</td><td align="left">Clinical trial</td><td align="left">Phenylalanine, tyrosine metabolism</td><td align="left"><p>Cancer</p><p>Inflammatory, autoimmune disease</p></td></tr><tr><td align="left">Glycogen synthase kinase-3 beta</td><td align="left">GSK-3&#x003b2;</td><td align="left">Research</td><td align="left">Glycogen biosynthesis</td><td align="left"><p>Cancer</p><p>Alzheimer&#x02019;s</p><p>Diabetes</p></td></tr><tr><td align="left">Hepatitis C virus (HCV) polymerase</td><td align="left">HS5B Pol</td><td align="left">Successful</td><td align="left">DNA biosynthesis</td><td align="left">Virus infection</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>The targets verified by HypoDB screening</p></table-wrap-foot></table-wrap>
</p><sec id="Sec12"><title>Analysis of the interaction network</title><p id="Par28">A topological analysis of the interaction network offered insights into the biologically relevant connectivity patterns, and highly influential compounds or targets. Some Chinese medicines had been investigated by interaction network analysis [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par29">The pharmacological network of <italic>M. cordata</italic> had three types of nodes (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The 26 alkaloid nodes formed the core of the network, and were surrounded by 65 target nodes. Each target was linked to at least one pathway. A total of 60 pathway nodes constituted the outer layer of the network. Each alkaloid was the center of a star-shaped action net except for the two bisbenzo<italic>[c]</italic>phenanthridines (BisBen), which were only linked to one target and one pathway, respectively. The alkaloids and targets were strongly interconnected in many-to-many relationships.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>The pharmacological network of <italic>Macleaya cordata</italic>. Hexagon, targets; Rectangle, biopathway; Ellipse, alkaloids (<italic>bright green</italic> Ben, <italic>dark green</italic> BisBen, <italic>breen</italic> Ber, <italic>orange</italic> Pro)</p></caption><graphic xlink:href="13020_2015_67_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par30">A general overview of the global topological properties of the network was obtained from the statistical data by the Network Analyzer of Cytoscape. The diameter of the network was 8.0, the centralization was 0.14, and the density was 0.024. The node degree indicated the number of edges linking to other nodes. The highly connected nodes were referred to as the hubs of the network. The degrees of all the alkaloids (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a) and important targets (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b) were investigated. The compounds with higher degree values, such as <bold>C5</bold>, <bold>C6</bold>, <bold>C9</bold>, <bold>C19</bold>, and <bold>C20</bold>, that might participate in more interactions than the other components were the hubs in the network. The target degree values mostly ranged between 2 and 7. The targets with the highest degree values included MIF (16), TTR (11), FabZ* (11), ER&#x003b1;* (10), and MR (10). The targets with higher degree values might be involved in the pharmacological actions of <italic>M. cordata.</italic>
<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Degree distribution in the network. <bold>a</bold> alkaloids, <bold>b</bold> targets</p></caption><graphic xlink:href="13020_2015_67_Fig6_HTML" id="MO6"/></fig>
</p></sec><sec id="Sec13"><title>Interpreting the pharmacological actions</title><p id="Par31">By mining the PubMed and TTD, the targets of <italic>M. cordata</italic> in the PharmaDB profiling results were annotated with biological functions and clinical indications (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Furthermore, the targets were classified according to the reported pharmacological activities of <italic>M. cordata</italic> as follows: microorganism (including bacterial, fungal, and viral) infection (12 targets, with 3 targets verified by HypoDB screening), parasitic disease (5 targets, with 2 targets validated by HypoDB screening), pain (3 targets), cancer (31 targets, with 8 targets confirmed by HypoDB screening), inflammation (8 targets, with 1 target verified by HypoDB screening), and injury (4 targets, with 2 targets fished by HypoDB screening).</p><sec id="Sec14"><title>Antibacterial activity</title><p id="Par32">The extracts and their purified alkaloids from <italic>M. cordata</italic> exhibited notable activities against <italic>Staphylococcus aureus</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Escherichia coli</italic>, <italic>Bacillus subtilis</italic>, <italic>Tetracoccus</italic> spp., and methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. In this study, 12 proposed targets were closely related to microorganisms, and seven of them exhibited antibacterial activities (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). the key types of alkaloids with antibacterial activity were dihydro-benzo<italic>[c]</italic>phenanthridine alkaloids and protoberberines.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>The compounds mapping of microorganism related targets</p></caption><graphic xlink:href="13020_2015_67_Fig7_HTML" id="MO7"/></fig>
</p><p id="Par33">Five targets (LmrR, TEM-1*, CAT, FNR, and ActR) were related to multidrug-resistant bacterial strains. LmrR, a multidrug binding transcriptional regulator and the predicted target of <bold>C11</bold>, was a PadR-related transcriptional repressor that regulated the production of LmrCD, a major multidrug ABC transporter in <italic>Lactococcus lactis</italic> [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. TEM-1* (TEM-1 <italic>beta</italic>-lactamase) fished by <bold>C19</bold> was one of the antibiotic-resistance determinants for penicillins, early cephalosporins, and novel drugs from their derivatives [<xref ref-type="bibr" rid="CR36">36</xref>]. A new drug, Avibactam&#x02122;, innovated by AstraZeneca is a TEM-1 inhibitor that has already entered phase III clinical development [<xref ref-type="bibr" rid="CR37">37</xref>]. In addition, chloramphenicol acetyltransferase (CAT), an antibiotic-inactivating enzyme predicted by <bold>C11</bold>, catalyzed the acetyl-<italic>S</italic>-CoA-dependent acetylation of chloramphenicol at the 3-hydroxyl group and resulted in chloramphenicol-resistance in bacteria [<xref ref-type="bibr" rid="CR38">38</xref>]. Ferredoxin-NADP<sup>+</sup> reductase (FNR), targeted in silico by <bold>C4</bold>, <bold>C5</bold>, <bold>C6</bold>, and <bold>C9</bold>, participated in numerous electron transfer reactions, had no homologous enzyme in humans, and was a target for the accumulation of multidrug-resistant microbial strains [<xref ref-type="bibr" rid="CR39">39</xref>]. The <italic>Streptomyces coelicolor</italic> TetR family protein ActR* was found by <bold>C19</bold>. ActR* may mediate timely self-resistance to an endogenously-produced antibiotic. TetR-mediated antibiotic-resistance might have been acquired from an antibiotic-producer organism [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par34">Two targets indicating other pathways were involved in the antibacterial activity. The ZipA-FtsZ complex was fished by <bold>C13</bold>, <bold>C14</bold>, and <bold>C20</bold> (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). ZipA was a membrane-anchored protein in <italic>E. coli</italic> that interacted with FtsZ-mediated bacterial cell division, and was considered a potential target for antibacterial agents [<xref ref-type="bibr" rid="CR41">41</xref>]. The target ENR catalyzed an essential step in fatty acid biosynthesis. ENR was a target for narrow-spectrum antibacterial drug discovery because of its essential role in metabolism and its sequence conservation across many bacterial species [<xref ref-type="bibr" rid="CR42">42</xref>].<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Three alkaloids mapped to ZipA-FtsZ. <italic>Left</italic> the crystal structure and pharmacophore of target, <italic>right</italic> the alkaloids fit to the pharmacophore</p></caption><graphic xlink:href="13020_2015_67_Fig8_HTML" id="MO8"/></fig>
</p></sec><sec id="Sec15"><title>Antiparasitic activity</title><p id="Par35">
<italic>M. cordata</italic> showed remarkable effects against <italic>Ichthyophthirius multifiliis</italic> in grass carp [<xref ref-type="bibr" rid="CR43">43</xref>] and richadsin [<xref ref-type="bibr" rid="CR44">44</xref>], as well as against <italic>Dactylogyrus intermedius</italic> in <italic>Carassius auratus</italic> [<xref ref-type="bibr" rid="CR45">45</xref>]. The total alkaloids of <italic>M. cordata</italic> were able to kill gastrointestinal parasites [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par36">In this study, five targets involved in parasitic diseases were predicted. Because of the lack of reported protein&#x02013;ligand crystal structures for parasitosis, these five targets were not related to the above parasitosis in either humans or other animals. However, the findings suggested the potential of <italic>M.</italic>
<italic>cordata</italic> to treat other parasitosis, such as malaria, Chagas disease, and Kala-azar. The enoyl-acyl carrier reductase PfENR* fished by two alkaloids (<bold>C5</bold> and <bold>C26</bold>) and the (3R)-hydroxymyristoyl acyl carrier protein dehydratase FabZ* in silico targeted by six alkaloids (<bold>C5</bold>, <bold>C6</bold>, <bold>C9</bold>, <bold>C11</bold>, <bold>C12</bold>, and <bold>C16</bold>) were involved in the fatty acid biosynthesis of <italic>Plasmodium falciparum</italic>. The antioxidant enzyme GR fished by <bold>C13</bold>, <bold>C14</bold>, and <bold>C19</bold> was a target for antimalarial drug development [<xref ref-type="bibr" rid="CR47">47</xref>]. The target glycosomal glyceraldehyde-3-phosphate dehydrogenase (GAPDH) found by <bold>C11</bold> was a target for the development of novel chemotherapeutic agents for the treatment of Chagas disease [<xref ref-type="bibr" rid="CR48">48</xref>]. Dihydroorotate dehydrogenase (DHODH) retrieved by <bold>C5</bold> and <bold>C6</bold> was related to both <italic>Leishmania</italic> infection and <italic>Trypanosoma</italic> infection [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec16"><title>Analgesic activity</title><p id="Par37">A mixture of the isoquinoline alkaloids from <italic>M. cordata</italic> exhibited strong analgesic activity towards the pain caused by inflammatory cytokines and direct peripheral nerve stimulation [<xref ref-type="bibr" rid="CR50">50</xref>]. In this study, three targets related to pain were identified. nAChR7&#x003b1; was abundantly expressed in the central and peripheral nervous systems, and involved in subchronic pain and inflammation [<xref ref-type="bibr" rid="CR51">51</xref>]. In the profiling results, nAChR7&#x003b1; was picked out by five alkaloids (<bold>C2</bold>, <bold>C11</bold>, <bold>C15</bold>, <bold>C19</bold>, and <bold>C25</bold>). MAPK p38 fished by <bold>C9</bold>, <bold>C14</bold>, and <bold>C20</bold> was involved in the development and maintenance of inflammatory pain [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. The reductase ALR fished by <bold>C19</bold> was a specific target of painful diabetic neuropathy [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Inhibitors of ALR relieved pain and improved somatic and autonomic nerve function [<xref ref-type="bibr" rid="CR56">56</xref>]. In addition, based on the action network, berberines (Ber) such as <bold>C19</bold> and <bold>C20</bold> may also be involved in the analgesic activity of <italic>M. cordata</italic>.</p></sec><sec id="Sec17"><title>Anti-inflammatory activity</title><p id="Par38">Eight targets related to inflammation were identified in this study. Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3&#x000a0;K&#x003b3;) fished by <bold>C19</bold> recruited leukocytes [<xref ref-type="bibr" rid="CR57">57</xref>]. The proteinase MMP12, also known as macrophage metalloelastase (MME) or macrophage elastase (ME), was identified with three fitted compounds (<bold>C3</bold>, <bold>C5</bold>, and <bold>C9</bold>) in this study. MMP12 mediated neutrophil and macrophage recruitment and T cell polarization [<xref ref-type="bibr" rid="CR58">58</xref>], and was a potential therapeutic target for asthma [<xref ref-type="bibr" rid="CR59">59</xref>]. PPAR&#x003b3;* fished by <bold>C3</bold> was another inflammation-related target. Some early findings demonstrated the anti-inflammatory effects of PPAR&#x003b3; by activating human or murine monocytes/macrophages and monocyte/macrophage cell lines [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par39">MAPK p38 was involved in a signaling cascade controlling cellular responses to inflammatory cytokines, and it was verified for this pathway in murine macrophage RAW264.7 cells that the <italic>M. cordata</italic> extract increased both the mRNA and protein levels of cytoprotective enzymes including heme oxygenase-1 (HO-1) and thioredoxin 1 via activation of the p38 MAPK/Nrf2 pathway [<xref ref-type="bibr" rid="CR16">16</xref>]. The kinase calcium/calmodulin-dependent protein kinase II (CAMKII) was a regulator of intracellular Ca<sup>2+</sup> levels, which triggered activation of the transcription factor nuclear factor-kappa B (NF-&#x003ba;B) after T-cell receptor stimulation. An inhibitory effect of CAMKII on NF-&#x003ba;B was confirmed [<xref ref-type="bibr" rid="CR61">61</xref>]. Phospholipase A2 (PLA2s) was a key enzyme in prostaglandin (PG) biosynthesis for discharging arachidonic acid. Selective inhibitors of PLA2s were implicated in inflammation and connected to diverse diseases, such as cancer, ischemia, atherosclerosis, and schizophrenia [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par40">The target mineralocorticoid receptor (MR) fished by five compounds (<bold>C3</bold>, <bold>C4</bold>, <bold>C6</bold>, <bold>C7</bold>, and <bold>C20</bold>) was activated by mineralocorticoids, such as aldosterone and deoxycorticosterone, as well as by glucocorticoids, like cortisol. Antagonists of MR had cardioprotective and anti-inflammatory effects in vivo via aldosterone-independent mechanisms [<xref ref-type="bibr" rid="CR63">63</xref>]. Macrophage migration inhibitory factor (MIF) was involved in both innate and adaptive immune responses. Inhibitors of MIF were potential anti-inflammatory agents [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par41">Seven of the eight predicted targets were also related to cancer. These dual correlative targets were PI3K&#x003b3;, MMP12, PPAR&#x003b3;*, MAPK p38, CAMKII, PLA2s, and MIF. Their matching compounds are shown in Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>, and the benzo<italic>[c]</italic>phenanthridine (Ben) alkaloids and berberine (Ber) alkaloids were involved in the anti-inflammatory activity.<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Alkaloid <bold>C11</bold> mapped to GAPDH. <italic>Left</italic> the crystal structure and pharmacophore of GAPDH, <italic>upper right</italic> the alkaloid <bold>C11</bold> docked into the target, <italic>lower</italic>
<italic>right</italic>
<bold>C11</bold> fitting into the pharmacophore and the shape of the pocket</p></caption><graphic xlink:href="13020_2015_67_Fig9_HTML" id="MO9"/></fig>
</p></sec><sec id="Sec18"><title>Injury healing activity</title><p id="Par42">In this study, four predicted targets (ER&#x003b1;*, ER&#x003b2;*, MR, and COMP) were involved in injury repair. Among them, ER&#x003b1;*, ER&#x003b2;*, and MR were linked with internal injuries, such as brain injury [<xref ref-type="bibr" rid="CR65">65</xref>], vascular injury [<xref ref-type="bibr" rid="CR66">66</xref>], and neuronal injury [<xref ref-type="bibr" rid="CR67">67</xref>]. The other target, cartilage oligomeric matrix protein (COMP), found by <bold>C9</bold> was a non-collagenous extracellular matrix protein found predominantly in cartilage, but also in tendon, ligament, and meniscus [<xref ref-type="bibr" rid="CR68">68</xref>]. COMP was a marker for joint destruction associated with osteoarthritis, rheumatoid arthritis, trauma, and intense activity [<xref ref-type="bibr" rid="CR69">69</xref>].</p></sec><sec id="Sec19"><title>Antitumor activity</title><p id="Par43">Both the mixed and single alkaloids of <italic>M. cordata</italic> strongly inhibited proliferation and induced apoptosis of cancer cells [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. The anticancer drug Ukrain&#x02122; is an isoquinoline type. The major components of Ukrain&#x02122; are chelidonine, sanguinarine, chelerythrine, protopine, and allocryptopine. Ukrain&#x02122; exerted cytotoxic effects in cancer cells without negative effects on normal cells [<xref ref-type="bibr" rid="CR71">71</xref>], and had radiosensitization effects on cancer cells, while exerting radioprotective effects on normal cells [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par44">In the pharmacological profiling results, almost half of the predicted targets (31 of 65 targets) had a close relationship with cancer, and ten of them (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) successfully entered into clinical trial observations. In total, nine targets related to cancer were fished by more than five compounds. The results revealed promising prospects for <italic>M. cordata</italic> in antitumor drug research and development. Based on the action network (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), possible antitumor molecular mechanisms of <italic>M.</italic>
<italic>cordata</italic> were analyzed as follows: (1) most possible effective targets and (2) most likely contributing compounds.</p><p id="Par45">The MIF column was particularly tall (Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>) because it was fished by 15 compounds, including all quaternary benzo<italic>[c]</italic>phenanthridine (Ben) alkaloids (<bold>C11&#x02013;C16</bold>), two other benzo<italic>[c]</italic>phenanthridine (Ben) alkaloids, five protoberberine (Ber) alkaloids, and two protopine (Pro) alkaloids. The discovered pathways of these 15 compounds mainly included NF-&#x003ba;B and ERK signaling pathways [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>], Bax/Bcl and caspase-dependent pathway [<xref ref-type="bibr" rid="CR75">75</xref>], ROS-mediated mitochondrial pathway [<xref ref-type="bibr" rid="CR76">76</xref>], p38 MAPK/Nrf2 pathway [<xref ref-type="bibr" rid="CR77">77</xref>], and VEGF-induced Akt phosphorylation pathway [<xref ref-type="bibr" rid="CR78">78</xref>]. All of these pathways were linked closely with MIF [<xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. However, there have been no experimental reports on to the interactions between MIF and these alkaloids.<fig id="Fig10"><label>Fig.&#x000a0;10</label><caption><p>The alkaloids mapping of cancer related targets</p></caption><graphic xlink:href="13020_2015_67_Fig10_HTML" id="MO10"/></fig>
</p><p id="Par46">Both transthyretin (TTR) and proto-oncogene serine threonine kinase* (PIM-1) were found by seven compounds. TTR was a biomarker for lung cancer [<xref ref-type="bibr" rid="CR85">85</xref>] and pancreatic ductal adenocarcinoma [<xref ref-type="bibr" rid="CR86">86</xref>], but has not yet been confirmed as a therapeutic target. PIM-1* fished by <bold>C5</bold>, <bold>C6</bold>, <bold>C8</bold>, <bold>C9</bold>, <bold>C14</bold>, <bold>C19</bold>, and <bold>C20</bold>, and also verified by HypoDB screening, was responsible for cell cycle regulation, antiapoptotic activity, mediation of homing, and migration of receptor tyrosine kinases via the JAK/STAT pathway. PIM-1 was upregulated in many hematological malignancies and solid tumors. Although PIM kinases were described as weak oncogenes, they were heavily targeted for anticancer drug discovery [<xref ref-type="bibr" rid="CR87">87</xref>]. <bold>C12</bold> was partially involved in the JAK/STAT pathway [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par47">The benzo<italic>[c]</italic>phenanthridine (Ben) alkaloids of <italic>M. cordata</italic> hit cancer-related targets a total of 75 times, compared with 25 times for protoberberines (Ber), five times for protopines (Pro), and one time for bis-benzo<italic>[c]</italic>phenanthridines (BisBen) (Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>). According to the quantitative determination of alkaloids from <italic>M. cordata</italic>, the quaternary benzo<italic>[c]</italic>phenanthridine alkaloids <bold>C12</bold>, <bold>C13</bold>, and <bold>C15</bold> were the main active components [<xref ref-type="bibr" rid="CR89">89</xref>]. However, the dihydro-benzo<italic>[c]</italic>phenanthridines such as <bold>C5</bold>, <bold>C6</bold>, and <bold>C9</bold> rarely reached the limit of detection (LOD), and hit more targets than the main alkaloids. As the quaternary and dihydro-benzo<italic>[c]</italic>phenanthridines can be transformed into one another, the dihydro-benzo<italic>[c]</italic>phenanthridines could be active compounds in vivo. The metabolism of <bold>C15</bold> was examined in pig liver microsomes and cytosol by electrospray ionization hybrid ion trap/time-of-flight mass spectrometry, and <bold>C7</bold> was one of the main metabolites in liver microsomes and the only metabolite in cytosol [<xref ref-type="bibr" rid="CR90">90</xref>]. Hence, the issue of whether the dihydro-benzo<italic>[c]</italic>phenanthridines were the main compounds combining with the targets in vivo requires further investigation.<fig id="Fig11"><label>Fig.&#x000a0;11</label><caption><p>The hit number of the alkaloids to cancer related targets</p></caption><graphic xlink:href="13020_2015_67_Fig11_HTML" id="MO11"/></fig>
</p><p id="Par48">Among the 31 cancer-related targets, at least seven (including MIF, PPAR&#x003b3;*, CAMKII, and Pi3K&#x003b3;) were involved in the immune system. These immune-associated targets might be crucial to for oncotherapy with <italic>M. cordata.</italic>
</p></sec></sec><sec id="Sec20"><title>Potential pharmacological activities</title><p id="Par49">According to the pharmacological profiling, some unreported pharmacological performances of <italic>M.</italic>
<italic>cordata</italic> emerged. In this study, 10 targets linked with neurodegeneration were fished, among which AChE and MAO-B were crucial therapeutic targets in Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR91">91</xref>&#x02013;<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par50">In addition, antiviral activities, especially anti-HIV, anti-SARS coronavirus, and antifungal activities, were kinds of extensions of the antibacterial function of <italic>M. cordata</italic>. The possible anti-HIV activity was notable, because HIV-1 reverse transcriptase and multidrug-resistant HIV-1 protease* were particularly related to AIDS [<xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR99">99</xref>]. Meanwhile, the anti-HIV activity was partly confirmed by HypoDB screening. The protein SARS-CoV M(pro) predicted by <bold>C3</bold> and <bold>C5</bold> was an attractive target for structure-based drug design of anti-SARS drugs owing to its indispensability for the maturation of severe acute respiratory syndrome coronavirus (SARS-CoV) [<xref ref-type="bibr" rid="CR100">100</xref>]. Another target, HS5B Pol, fished by five alkaloids was a target for anti-HCV therapeutic advances [<xref ref-type="bibr" rid="CR101">101</xref>]. Inhibitors of HS5B Pol would be a principal option for the treatment of HCV [<xref ref-type="bibr" rid="CR102">102</xref>]. Meanwhile, scytalone dehydratase and negative transcriptional regulator NmrA were suggested to be physiological targets of new fungicides and the subjects of inhibitor design and optimization [<xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par51">In this paper, we proposed a very wide range of the promising targets for the isoquinoline alkaloids of <italic>M. cordata</italic>. Most of the hits are not yet proven by pharmacological experiment.</p></sec></sec><sec id="Sec21" sec-type="conclusion"><title>Conclusion</title><p id="Par52">Through in silicotarget fishing, the anticancer, anti-inflammatory, and analgesic effects of <italic>M. cordata</italic> were the most significant among many possible activities. The possible anticancer effects were mainly contributed by the isoquinoline alkaloids as active components.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CHARMM</term><def><p id="Par5">chemistry at Harvard Macromolecular Mechanics</p></def></def-item><def-item><term>MOE</term><def><p id="Par6">molecular operating environment</p></def></def-item><def-item><term>RMSD</term><def><p id="Par7">root mean square deviation</p></def></def-item><def-item><term>MMFF</term><def><p id="Par8">Merck molecular force field</p></def></def-item><def-item><term>PDB</term><def><p id="Par9">Protein Data Bank</p></def></def-item><def-item><term>KEGG</term><def><p id="Par10">Kyoto Encyclopedia of genes and genomes</p></def></def-item><def-item><term>TTD</term><def><p id="Par11">Therapeutic Target Database</p></def></def-item><def-item><term>HTML</term><def><p id="Par12">hypertext markup language</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>HBL, QFL, PGX and YP conceived and designed the study. HBL, QFL and PGX performed the experiments. HBL, QFL and YP wrote the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par53">The authors would like to thank Prof. Jun Xu (Sun Yat-sen University, China) and Prof. Yanze Liu (IMPLAD, China) for assistance in preparing the manuscript and Dr. Rong Zhao (National Yang-Ming University, Taiwan) for assistance in analyzing the pathway. This work was supported by National Natural Science Foundation of China (Grant No. 81072995), and Peking Union Medical College Youth Fund (Grant No. 3332013079).</p></sec><sec id="FPar2" sec-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare that they have no competing interests.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Xu GJ, Wang Q, Yu BM. Color illustrations of antitumor traditional Chinese medicine. Fuzhou: Fujian Sci Technol Publ House; 1997. p. 759.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Grieve M. A modern herbal. Middlesex: Penguin Books; 1984.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Duke JA, Ayenus ES. Medicinal plants of China. Inc. Algonac: Reference Publications; 1984.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psotova</surname><given-names>J</given-names></name><name><surname>Vecera</surname><given-names>R</given-names></name><name><surname>Zdarilova</surname><given-names>A</given-names></name><name><surname>Anzenbacherova</surname><given-names>E</given-names></name><name><surname>Kosina</surname><given-names>P</given-names></name><name><surname>Svobodova</surname><given-names>A</given-names></name><name><surname>Hrbac</surname><given-names>J</given-names></name></person-group><article-title>Safety assessment of sanguiritrin, alkaloid fraction of <italic>Macleaya cordata</italic>, in rats</article-title><source>Vet Med-Czech</source><year>2006</year><volume>51</volume><issue>4</issue><fpage>145</fpage><lpage>155</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>JX</given-names></name><name><surname>Ma</surname><given-names>RQ</given-names></name><name><surname>Liu</surname><given-names>LM</given-names></name><name><surname>Jiang</surname><given-names>YP</given-names></name><name><surname>Sun</surname><given-names>LS</given-names></name></person-group><article-title>In vitro cytotoxic effect on Hep3B cells and in vivo antitumor effect in mice</article-title><source>J First Mil Med Univ</source><year>2005</year><volume>25</volume><issue>3</issue><fpage>325</fpage><lpage>328</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>QF</given-names></name><name><surname>Xiang</surname><given-names>JF</given-names></name><name><surname>Tang</surname><given-names>YL</given-names></name><name><surname>Xu</surname><given-names>GZ</given-names></name></person-group><article-title>Antitumor effect of <italic>Macleaya cordata</italic> and its molecular mechanism on inducement of human telomeric DNA to form G-quadruplex</article-title><source>Chin Trad Herb Drugs</source><year>2011</year><volume>42</volume><issue>4</issue><fpage>738</fpage><lpage>742</lpage></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Pang FG. Study on the Anticancer Constituents of <italic>Macleaya cordata</italic> (Willd) R.Br. Master Thesis. Shenyang Pharmaceutical University; 2005.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemeny-Beke</surname><given-names>A</given-names></name><name><surname>Aradi</surname><given-names>J</given-names></name><name><surname>Damjanovich</surname><given-names>J</given-names></name><name><surname>Beck</surname><given-names>Z</given-names></name><name><surname>Facsko</surname><given-names>A</given-names></name><name><surname>Berta</surname><given-names>A</given-names></name><name><surname>Bodnar</surname><given-names>A</given-names></name></person-group><article-title>Apoptotic response of uveal melanoma cells upon treatment with chelidonine, sanguinarine and chelerythrine</article-title><source>Cancer Lett</source><year>2006</year><volume>237</volume><issue>1</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.05.037</pub-id><?supplied-pmid 16019128?><pub-id pub-id-type="pmid">16019128</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenfeld</surname><given-names>J</given-names></name><name><surname>Kroutil</surname><given-names>M</given-names></name><name><surname>Mars&#x000e1;lek</surname><given-names>E</given-names></name><name><surname>Slavik</surname><given-names>J</given-names></name><name><surname>Preininger</surname><given-names>V</given-names></name><name><surname>Sim&#x000e1;nek</surname><given-names>V</given-names></name></person-group><article-title>Antiinflammatory activity of quaternary benzophenanthridine alkaloids from <italic>Chelidonium majus</italic></article-title><source>Planta Med</source><year>1981</year><volume>43</volume><issue>2</issue><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1055/s-2007-971493</pub-id><?supplied-pmid 7312984?><pub-id pub-id-type="pmid">7312984</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Cuong</surname><given-names>TD</given-names></name><name><surname>Hung</surname><given-names>TM</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Na</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Ryoo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><name><surname>Woo</surname><given-names>MH</given-names></name></person-group><article-title>Alkaloids from <italic>Chelidonium majus</italic> and their inhibitory effects on LPS-induced NO production in RAW264.7 cells</article-title><source>Bioorg Med Chem Lett</source><year>2011</year><volume>21</volume><fpage>6960</fpage><lpage>6963</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.09.128</pub-id><?supplied-pmid 22024033?><pub-id pub-id-type="pmid">22024033</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>BY</given-names></name><name><surname>Liu</surname><given-names>DM</given-names></name><name><surname>Zeng</surname><given-names>JG</given-names></name></person-group><article-title>Protective effect of <italic>Macleaya cordata</italic> extract on alcohol-induced acute hepatic injury in rats</article-title><source>Cent South Pharm</source><year>2011</year><volume>9</volume><issue>7</issue><fpage>485</fpage><lpage>489</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosina</surname><given-names>P</given-names></name><name><surname>Gregorova</surname><given-names>J</given-names></name><name><surname>Gruz</surname><given-names>J</given-names></name><name><surname>Vacek</surname><given-names>J</given-names></name><name><surname>Kolar</surname><given-names>M</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>W</given-names></name><name><surname>Naumann</surname><given-names>K</given-names></name><name><surname>Simanek</surname><given-names>V</given-names></name><name><surname>Ulrichova</surname><given-names>J</given-names></name></person-group><article-title>Phytochemical and antimicrobial characterization of <italic>Macleaya cordata</italic> herb</article-title><source>Fitoterapia</source><year>2010</year><volume>81</volume><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2010.06.020</pub-id><?supplied-pmid 20600683?><pub-id pub-id-type="pmid">20600683</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>RB</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>GH</given-names></name></person-group><article-title>Effect of Chelerythrine on glucosyltransferase and water-insoluble glucan of <italic>Streptococcus mutans</italic></article-title><source>Shanghai J Stomatol</source><year>2007</year><volume>16</volume><issue>3</issue><fpage>324</fpage><lpage>327</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JP</given-names></name><name><surname>Zhao</surname><given-names>DL</given-names></name><name><surname>Meng</surname><given-names>XB</given-names></name><name><surname>Zhou</surname><given-names>XQ</given-names></name></person-group><article-title>The antibacterial effect of the alkaloids from <italic>Macleaya cordata</italic> on eight kinds of fungi</article-title><source>J Mount Agri Biol</source><year>2006</year><volume>25</volume><issue>1</issue><fpage>89</fpage><lpage>91</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>KO</given-names></name><name><surname>Ghorbani</surname><given-names>M</given-names></name><name><surname>Schilcher</surname><given-names>H</given-names></name></person-group><article-title>Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and <italic>Chelidonium majus</italic> extracts on isolated guinea-pig ileum</article-title><source>Planta Med</source><year>1998</year><volume>64</volume><issue>8</issue><fpage>758</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1055/s-2006-957576</pub-id><?supplied-pmid 9933996?><pub-id pub-id-type="pmid">9933996</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrba</surname><given-names>J</given-names></name><name><surname>Orolinova</surname><given-names>E</given-names></name><name><surname>Ulrichova</surname><given-names>J</given-names></name></person-group><article-title>Induction of heme oxygenase-1 by <italic>Macleaya cordata</italic> extract and its constituent sanguinarine in RAW264.7 cells</article-title><source>Fitoterapia</source><year>2012</year><volume>83</volume><issue>2</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2011.11.022</pub-id><?supplied-pmid 22166397?><pub-id pub-id-type="pmid">22166397</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>QF</given-names></name><name><surname>Zhao</surname><given-names>XL</given-names></name><name><surname>Xu</surname><given-names>LJ</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>PG</given-names></name></person-group><article-title>Chemical constituents of plants from tribe Chelidonieae and their bioactivities</article-title><source>Chin Herb Med</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S1674-6384(14)60001-0</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LJ</given-names></name><name><surname>Leung</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>DS</given-names></name><name><surname>Susanti</surname><given-names>D</given-names></name><name><surname>Rao</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>PW</given-names></name><name><surname>Ma</surname><given-names>DL</given-names></name><name><surname>Leung</surname><given-names>CH</given-names></name></person-group><article-title>Pharmacophore modeling for the identification of small-molecule inhibitors of TACE</article-title><source>Methods</source><year>2015</year><volume>71</volume><issue>1</issue><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2014.09.005</pub-id><?supplied-pmid 25260600?><pub-id pub-id-type="pmid">25260600</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>HJ</given-names></name><name><surname>Liu</surname><given-names>LJ</given-names></name><name><surname>Chong</surname><given-names>CM</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>DS</given-names></name><name><surname>Chan</surname><given-names>PW</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Ma</surname><given-names>DL</given-names></name><name><surname>Leung</surname><given-names>CH</given-names></name></person-group><article-title>Discovery of a natural product-like iNOS inhibitor by molecular docking with potential neuroprotective effects in vivo</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>4</issue><fpage>e92905</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0092905</pub-id><?supplied-pmid 24690920?><pub-id pub-id-type="pmid">24690920</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>DL</given-names></name><name><surname>Chan</surname><given-names>DS</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Zhong</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Leung</surname><given-names>LT</given-names></name><name><surname>Gullen</surname><given-names>EA</given-names></name><name><surname>Chiu</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>YC</given-names></name><name><surname>Leung</surname><given-names>CH</given-names></name></person-group><article-title>Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library</article-title><source>Chem Commun (Camb)</source><year>2014</year><volume>50</volume><issue>90</issue><fpage>13885</fpage><lpage>13888</lpage><pub-id pub-id-type="doi">10.1039/C4CC04498C</pub-id><pub-id pub-id-type="pmid">25225654</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name></person-group><article-title>TarFisDock: a web server for identifying drug targets with docking approach</article-title><source>Nucleic Acids Res</source><year>2006</year><volume>34</volume><issue>suppl 2</issue><fpage>W219</fpage><lpage>W224</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl114</pub-id><?supplied-pmid 16844997?><pub-id pub-id-type="pmid">16844997</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>D</given-names></name></person-group><article-title>3D pharmacophores as tools for activity profiling</article-title><source>Drug Discov Today Tech</source><year>2010</year><volume>7</volume><issue>4</issue><fpage>e205</fpage><lpage>e211</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2010.11.006</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steindl</surname><given-names>TM</given-names></name><name><surname>Schuster</surname><given-names>D</given-names></name><name><surname>Laggner</surname><given-names>C</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><article-title>Parallel screening: a novel concept in pharmacophore modelling and virtual screening</article-title><source>J Chem Inf Model</source><year>2006</year><volume>46</volume><issue>5</issue><fpage>2146</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1021/ci6002043</pub-id><?supplied-pmid 16995745?><pub-id pub-id-type="pmid">16995745</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steindl</surname><given-names>TM</given-names></name><name><surname>Schuster</surname><given-names>D</given-names></name><name><surname>Wolber</surname><given-names>G</given-names></name><name><surname>Laggner</surname><given-names>C</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><article-title>High throughput structure-based pharmacophore modeling as a basis for successful parallel virtual screening</article-title><source>J Comput Aided Mol Des</source><year>2006</year><volume>20</volume><issue>12</issue><fpage>703</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1007/s10822-006-9066-y</pub-id><?supplied-pmid 17009092?><pub-id pub-id-type="pmid">17009092</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meslamani</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sutter</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Bertrand</surname><given-names>HO</given-names></name><name><surname>Rognan</surname><given-names>D</given-names></name></person-group><article-title>Protein&#x02013;ligand-based pharmacophores: generation and utility assessment in computational ligand profiling</article-title><source>J Chem Inf Model</source><year>2012</year><volume>52</volume><issue>4</issue><fpage>943</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1021/ci300083r</pub-id><?supplied-pmid 22480372?><pub-id pub-id-type="pmid">22480372</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meslamani</surname><given-names>J</given-names></name><name><surname>Rognan</surname><given-names>D</given-names></name><name><surname>Kellenberger</surname><given-names>E</given-names></name></person-group><article-title>sc-PDB: a database for identifying variations and multiplicity of &#x02018;druggable&#x02019; binding sites in proteins</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><issue>9</issue><fpage>1324</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr120</pub-id><?supplied-pmid 21398668?><pub-id pub-id-type="pmid">21398668</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>D1</issue><fpage>D1128</fpage><lpage>D1136</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr797</pub-id><?supplied-pmid 21948793?><pub-id pub-id-type="pmid">21948793</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Law</surname><given-names>V</given-names></name><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ly</surname><given-names>S</given-names></name><name><surname>Frolkis</surname><given-names>A</given-names></name><name><surname>Pon</surname><given-names>A</given-names></name><name><surname>Banco</surname><given-names>K</given-names></name><name><surname>Mak</surname><given-names>C</given-names></name><name><surname>Neveu</surname><given-names>V</given-names></name></person-group><article-title>DrugBank 3.0: a comprehensive resource for &#x02018;omics&#x02019; research on drugs</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>suppl 1</issue><fpage>D1035</fpage><lpage>D1041</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1126</pub-id><?supplied-pmid 21059682?><pub-id pub-id-type="pmid">21059682</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smoot</surname><given-names>ME</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Ruscheinski</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>PL</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><article-title>Cytoscape 2.8: new features for data integration and network visualization</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><issue>3</issue><fpage>431</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq675</pub-id><?supplied-pmid 21149340?><pub-id pub-id-type="pmid">21149340</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrman</surname><given-names>TM</given-names></name><name><surname>Barlow</surname><given-names>DJ</given-names></name><name><surname>Hylands</surname><given-names>PJ</given-names></name></person-group><article-title>In silico search for multi-target anti-inflammatories in Chinese herbs and formulas</article-title><source>Bioorg Med Chem</source><year>2010</year><volume>18</volume><issue>6</issue><fpage>2204</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.01.070</pub-id><?supplied-pmid 20188577?><pub-id pub-id-type="pmid">20188577</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>A systems biology approach to understanding the mechanisms of action of Chinese herbs for treatment of cardiovascular disease</article-title><source>Int J Mol Sci</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>13501</fpage><lpage>13520</lpage><pub-id pub-id-type="doi">10.3390/ijms131013501</pub-id><?supplied-pmid 23202964?><pub-id pub-id-type="pmid">23202964</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>A system-level investigation into the mechanisms of Chinese Traditional Medicine: compound Danshen formula for cardiovascular disease treatment</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><fpage>e43918</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0043918</pub-id><?supplied-pmid 22962593?><pub-id pub-id-type="pmid">22962593</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>DL</given-names></name><name><surname>Yu</surname><given-names>JP</given-names></name><name><surname>Zhou</surname><given-names>XQ</given-names></name></person-group><article-title>Antibacterial effect of the Sanguinarine Hydrochloride and Bocconoline from <italic>Macleaya cordata</italic></article-title><source>Food Sci</source><year>2005</year><volume>26</volume><issue>1</issue><fpage>45</fpage><lpage>47</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fibriansah</surname><given-names>G</given-names></name><name><surname>Kovacs</surname><given-names>AT</given-names></name><name><surname>Pool</surname><given-names>TJ</given-names></name><name><surname>Boonstra</surname><given-names>M</given-names></name><name><surname>Kuipers</surname><given-names>OP</given-names></name><name><surname>Thunnissen</surname><given-names>AM</given-names></name></person-group><article-title>Crystal structures of two transcriptional regulators from <italic>Bacillus cereus</italic> define the conserved structural features of a PadR subfamily</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e48015</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0048015</pub-id><?supplied-pmid 23189126?><pub-id pub-id-type="pmid">23189126</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agustiandari</surname><given-names>H</given-names></name><name><surname>Peeters</surname><given-names>E</given-names></name><name><surname>de Wit</surname><given-names>JG</given-names></name><name><surname>Charlier</surname><given-names>D</given-names></name><name><surname>Driessen</surname><given-names>AJ</given-names></name></person-group><article-title>LmrR-mediated gene regulation of multidrug resistance in <italic>Lactococcus lactis</italic></article-title><source>Microbiology</source><year>2011</year><volume>157</volume><issue>Pt 5</issue><fpage>1519</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1099/mic.0.048025-0</pub-id><?supplied-pmid 21330438?><pub-id pub-id-type="pmid">21330438</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salverda</surname><given-names>ML</given-names></name><name><surname>De Visser</surname><given-names>JA</given-names></name><name><surname>Barlow</surname><given-names>M</given-names></name></person-group><article-title>Natural evolution of TEM-1 beta-lactamase: experimental reconstruction and clinical relevance</article-title><source>FEMS Microbiol Rev</source><year>2010</year><volume>34</volume><issue>6</issue><fpage>1015</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00222.x</pub-id><?supplied-pmid 20412308?><pub-id pub-id-type="pmid">20412308</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehmann</surname><given-names>DE</given-names></name><name><surname>Jahic</surname><given-names>H</given-names></name><name><surname>Ross</surname><given-names>PL</given-names></name><name><surname>Gu</surname><given-names>RF</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Kern</surname><given-names>G</given-names></name><name><surname>Walkup</surname><given-names>GK</given-names></name><name><surname>Fisher</surname><given-names>SL</given-names></name></person-group><article-title>Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor</article-title><source>Proc Natl Acad Sci USA</source><year>2012</year><volume>109</volume><issue>29</issue><fpage>11663</fpage><lpage>11668</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205073109</pub-id><?supplied-pmid 22753474?><pub-id pub-id-type="pmid">22753474</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>WV</given-names></name></person-group><article-title>Chloramphenicol acetyltransferase: enzymology and molecular biology</article-title><source>CRC Crit Rev Biochem</source><year>1983</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.3109/10409238309102789</pub-id><?supplied-pmid 6340955?><pub-id pub-id-type="pmid">6340955</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalano-Dupuy</surname><given-names>DL</given-names></name><name><surname>Lopez-Rivero</surname><given-names>A</given-names></name><name><surname>Soldano</surname><given-names>A</given-names></name><name><surname>Ceccarelli</surname><given-names>EA</given-names></name></person-group><article-title>Redox proteins as targets for drugs development against pathogens</article-title><source>Curr Pharm Des</source><year>2013</year><volume>19</volume><issue>14</issue><fpage>2594</fpage><lpage>2605</lpage><pub-id pub-id-type="doi">10.2174/1381612811319140009</pub-id><?supplied-pmid 23116397?><pub-id pub-id-type="pmid">23116397</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>AR</given-names></name><name><surname>Tahlan</surname><given-names>K</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>ZZ</given-names></name><name><surname>Ichinose</surname><given-names>K</given-names></name><name><surname>Junop</surname><given-names>MS</given-names></name><name><surname>Nodwell</surname><given-names>JR</given-names></name></person-group><article-title>Crystal structures of the <italic>Streptomyces coelicolor</italic>TetR-like protein ActR alone and in complex with actinorhodin or the actinorhodin biosynthetic precursor (S)-DNPA</article-title><source>J Mol Biol</source><year>2008</year><volume>376</volume><issue>5</issue><fpage>1377</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.12.061</pub-id><?supplied-pmid 18207163?><pub-id pub-id-type="pmid">18207163</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>DH</given-names></name><name><surname>Sutherland</surname><given-names>AG</given-names></name><name><surname>Jennings</surname><given-names>LD</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Rush</surname><given-names>TR</given-names></name><name><surname>Alvarez</surname><given-names>JC</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Dushin</surname><given-names>EG</given-names></name><name><surname>Dushin</surname><given-names>RG</given-names></name><name><surname>Haney</surname><given-names>SA</given-names></name></person-group><article-title>Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design</article-title><source>Bioorg Med Chem</source><year>2006</year><volume>14</volume><issue>23</issue><fpage>7953</fpage><lpage>7961</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.07.050</pub-id><?supplied-pmid 16919463?><pub-id pub-id-type="pmid">16919463</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>LL</given-names></name><name><surname>Xian</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Mills</surname><given-names>DM</given-names></name><name><surname>Arvanites</surname><given-names>AC</given-names></name><name><surname>Orgueira</surname><given-names>H</given-names></name><name><surname>Ashwell</surname><given-names>MA</given-names></name><name><surname>Carmel</surname><given-names>G</given-names></name></person-group><article-title>Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><issue>5</issue><fpage>1541</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.5.1541-1547.2004</pub-id><?supplied-pmid 15105103?><pub-id pub-id-type="pmid">15105103</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>JY</given-names></name><name><surname>Shen</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>GJ</given-names></name><name><surname>Pan</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>GX</given-names></name><name><surname>Yin</surname><given-names>WL</given-names></name></person-group><article-title>Effect of sanguinarine from the leaves of <italic>Macleaya cordata</italic> against <italic>Ichthyophthirius multifiliis</italic> in grass carp (<italic>Ctenopharyngodon idella</italic>)</article-title><source>Parasitol Res</source><year>2010</year><volume>107</volume><issue>5</issue><fpage>1035</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1007/s00436-010-1966-z</pub-id><?supplied-pmid 20625767?><pub-id pub-id-type="pmid">20625767</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>JY</given-names></name><name><surname>Zhou</surname><given-names>ZM</given-names></name><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>Yin</surname><given-names>WL</given-names></name><name><surname>Ru</surname><given-names>HS</given-names></name><name><surname>Pan</surname><given-names>XY</given-names></name><name><surname>Hao</surname><given-names>GJ</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>JY</given-names></name></person-group><article-title>Antiparasitic efficacy of dihydrosanguinarine and dihydrochelerythrine from <italic>Macleaya microcarpa</italic> against <italic>Ichthyophthirius multifiliis</italic> in richadsin (<italic>Squaliobarbus curriculus</italic>)</article-title><source>Vet Parasitol</source><year>2011</year><volume>183</volume><issue>1&#x02013;2</issue><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2011.07.021</pub-id><?supplied-pmid 21813242?><pub-id pub-id-type="pmid">21813242</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GX</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>DX</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Zhao</surname><given-names>LW</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>In vivo anthelmintic activity of five alkaloids from <italic>Macleaya microcarpa</italic> (Maxim) Fedde against <italic>Dactylogyru sintermedius</italic> in Carassiusauratus</article-title><source>Vet Parasitol</source><year>2010</year><volume>171</volume><issue>3&#x02013;4</issue><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2010.03.032</pub-id><?supplied-pmid 20413222?><pub-id pub-id-type="pmid">20413222</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juskiewicz</surname><given-names>J</given-names></name><name><surname>Gruzauskas</surname><given-names>R</given-names></name><name><surname>Zdunczyk</surname><given-names>Z</given-names></name><name><surname>Semaskaite</surname><given-names>A</given-names></name><name><surname>Jankowski</surname><given-names>J</given-names></name><name><surname>Totilas</surname><given-names>Z</given-names></name><name><surname>Jarule</surname><given-names>V</given-names></name><name><surname>Sasyte</surname><given-names>V</given-names></name><name><surname>Zdunczyk</surname><given-names>P</given-names></name></person-group><article-title>Raceviciute-StupelieneA: effects of dietary addition of <italic>Macleaya cordata</italic> alkaloid extract on growth performance, caecal indices and breast meat fatty acids profile in male broilers</article-title><source>J Anim Physiol Anim Nutr (Berl)</source><year>2011</year><volume>95</volume><issue>2</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0396.2010.01037.x</pub-id><pub-id pub-id-type="pmid">20666860</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarma</surname><given-names>GN</given-names></name><name><surname>Savvides</surname><given-names>SN</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Schirmer</surname><given-names>M</given-names></name><name><surname>Schirmer</surname><given-names>RH</given-names></name><name><surname>Karplus</surname><given-names>PA</given-names></name></person-group><article-title>Glutathione reductase of the malarial parasite <italic>Plasmodium falciparum</italic>: crystal structure and inhibitor development</article-title><source>J Mol Biol</source><year>2003</year><volume>328</volume><issue>4</issue><fpage>893</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00347-4</pub-id><?supplied-pmid 12729762?><pub-id pub-id-type="pmid">12729762</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leit&#x000e3;o</surname><given-names>A</given-names></name><name><surname>Andricopulo</surname><given-names>AD</given-names></name><name><surname>Oliva</surname><given-names>G</given-names></name><name><surname>Pupo</surname><given-names>MT</given-names></name><name><surname>de Marchi</surname><given-names>AA</given-names></name><name><surname>Vieira</surname><given-names>PC</given-names></name><name><surname>da Silva</surname><given-names>MF</given-names></name><name><surname>Ferreira</surname><given-names>VF</given-names></name><name><surname>de Souza</surname><given-names>MC</given-names></name><name><surname>S&#x000e1;</surname><given-names>MM</given-names></name><name><surname>Moraes</surname><given-names>VR</given-names></name><name><surname>Montanari</surname><given-names>CA</given-names></name></person-group><article-title>Structure&#x02013;activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase</article-title><source>Bioorg Med Chem Lett</source><year>2004</year><volume>14</volume><issue>9</issue><fpage>2199</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.02.025</pub-id><?supplied-pmid 15081008?><pub-id pub-id-type="pmid">15081008</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>MP</given-names></name><name><surname>Emery</surname><given-names>FS</given-names></name><name><surname>Nonato</surname><given-names>MC</given-names></name></person-group><article-title>Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotatedehydrogenase</article-title><source>Curr Pharm Des</source><year>2013</year><volume>19</volume><issue>14</issue><fpage>2615</fpage><lpage>2627</lpage><pub-id pub-id-type="doi">10.2174/1381612811319140011</pub-id><?supplied-pmid 23116399?><pub-id pub-id-type="pmid">23116399</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>YT</given-names></name><name><surname>Ju</surname><given-names>CY</given-names></name><name><surname>Yan</surname><given-names>HR</given-names></name><name><surname>Sun</surname><given-names>LQ</given-names></name></person-group><article-title>Experimental research on analgesic effect of the total alkaloid from Celandine</article-title><source>J Mudanjiang Med Univ</source><year>2011</year><volume>32</volume><issue>6</issue><fpage>29</fpage><lpage>30</lpage></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>K</given-names></name><name><surname>Carroll</surname><given-names>FI</given-names></name><name><surname>Damaj</surname><given-names>MI</given-names></name></person-group><article-title>The antinociceptive effects of nicotinic receptors alpha7-positive allosteric modulators in murine acute and tonic pain models</article-title><source>J Pharmacol Exp Ther</source><year>2013</year><volume>344</volume><issue>1</issue><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1124/jpet.112.197871</pub-id><?supplied-pmid 23115222?><pub-id pub-id-type="pmid">23115222</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medicherla</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>M</given-names></name><name><surname>Ying</surname><given-names>J</given-names></name><name><surname>Navas</surname><given-names>TA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>AN</given-names></name><name><surname>Kerr</surname><given-names>I</given-names></name><name><surname>Hanjarappa</surname><given-names>N</given-names></name><name><surname>Protter</surname><given-names>AA</given-names></name><name><surname>Higgins</surname><given-names>LS</given-names></name></person-group><article-title>p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma</article-title><source>Anticancer Res</source><year>2008</year><volume>28</volume><issue>6A</issue><fpage>3827</fpage><lpage>3833</lpage><?supplied-pmid 19189670?><pub-id pub-id-type="pmid">19189670</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufer</surname><given-names>S</given-names></name><name><surname>Lehmann</surname><given-names>F</given-names></name></person-group><article-title>Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase</article-title><source>Bioorg Med Chem Lett</source><year>2009</year><volume>19</volume><issue>5</issue><fpage>1461</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.01.023</pub-id><?supplied-pmid 19195885?><pub-id pub-id-type="pmid">19195885</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steuber</surname><given-names>H</given-names></name><name><surname>Heine</surname><given-names>A</given-names></name><name><surname>Klebe</surname><given-names>G</given-names></name></person-group><article-title>Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution</article-title><source>J Mol Biol</source><year>2007</year><volume>368</volume><issue>3</issue><fpage>618</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.12.004</pub-id><?supplied-pmid 17368668?><pub-id pub-id-type="pmid">17368668</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryanarayana</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>PA</given-names></name><name><surname>Saraswat</surname><given-names>M</given-names></name><name><surname>Petrash</surname><given-names>JM</given-names></name><name><surname>Reddy</surname><given-names>GB</given-names></name></person-group><article-title>Inhibition of aldose reductase by tannoid principles of <italic>Emblica officinalis</italic>: implications for the prevention of sugar cataract</article-title><source>Mol Vis</source><year>2004</year><volume>10</volume><fpage>148</fpage><lpage>154</lpage><?supplied-pmid 15031705?><pub-id pub-id-type="pmid">15031705</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>RJ</given-names></name><name><surname>Ewing</surname><given-names>DJ</given-names></name><name><surname>Clarke</surname><given-names>BF</given-names></name></person-group><article-title>A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy</article-title><source>Diabetes</source><year>1983</year><volume>32</volume><issue>10</issue><fpage>938</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.2337/diab.32.10.938</pub-id><?supplied-pmid 6225686?><pub-id pub-id-type="pmid">6225686</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Solinas</surname><given-names>G</given-names></name></person-group><article-title>Inhibition of phosphoinositide 3-kinase gamma attenuates inflammation, obesity, and cardiovascular risk factors</article-title><source>Ann N Y Acad Sci</source><year>2013</year><volume>1280</volume><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/nyas.12037</pub-id><?supplied-pmid 23551103?><pub-id pub-id-type="pmid">23551103</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufour</surname><given-names>A</given-names></name><name><surname>Overall</surname><given-names>CM</given-names></name></person-group><article-title>Missing the target: matrix metalloproteinase antitargets in inflammation and cancer</article-title><source>Trends Pharmacol Sci</source><year>2013</year><volume>34</volume><issue>4</issue><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2013.02.004</pub-id><?supplied-pmid 23541335?><pub-id pub-id-type="pmid">23541335</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Sypek</surname><given-names>J</given-names></name><name><surname>Tavendale</surname><given-names>R</given-names></name><name><surname>Gartner</surname><given-names>U</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Page</surname><given-names>K</given-names></name><name><surname>Fleming</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>J</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>M</given-names></name></person-group><article-title>Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><issue>1</issue><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.03.027</pub-id><?supplied-pmid 20546881?><pub-id pub-id-type="pmid">20546881</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RB</given-names></name></person-group><article-title>The role of PPARs in inflammation and immunity</article-title><source>J Leukoc Biol</source><year>2002</year><volume>71</volume><issue>3</issue><fpage>388</fpage><lpage>400</lpage><?supplied-pmid 11867676?><pub-id pub-id-type="pmid">11867676</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maubach</surname><given-names>G</given-names></name><name><surname>Sokolova</surname><given-names>O</given-names></name><name><surname>Wolfien</surname><given-names>M</given-names></name><name><surname>Rothkotter</surname><given-names>HJ</given-names></name><name><surname>Naumann</surname><given-names>M</given-names></name></person-group><article-title>Ca/calmodulin-dependent kinase II contributes to inhibitor of nuclear factor-kappa B kinase complex activation in <italic>Helicobacter pylori</italic> infection</article-title><source>Int J Cancer</source><year>2013</year><volume>133</volume><issue>6</issue><fpage>1507</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1002/ijc.28148</pub-id><?supplied-pmid 23463379?><pub-id pub-id-type="pmid">23463379</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalka</surname><given-names>AK</given-names></name><name><surname>Kinnunen</surname><given-names>PK</given-names></name></person-group><article-title>Class specific peptide inhibitors for secretory phospholipases A2</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>436</volume><issue>2</issue><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.05.110</pub-id><?supplied-pmid 23747420?><pub-id pub-id-type="pmid">23747420</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usher</surname><given-names>MG</given-names></name><name><surname>Duan</surname><given-names>SZ</given-names></name><name><surname>Ivaschenko</surname><given-names>CY</given-names></name><name><surname>Frieler</surname><given-names>RA</given-names></name><name><surname>Berger</surname><given-names>S</given-names></name><name><surname>Schutz</surname><given-names>G</given-names></name><name><surname>Lumeng</surname><given-names>CN</given-names></name><name><surname>Mortensen</surname><given-names>RM</given-names></name></person-group><article-title>Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><issue>9</issue><fpage>3350</fpage><lpage>3364</lpage><pub-id pub-id-type="doi">10.1172/JCI41080</pub-id><?supplied-pmid 20697155?><pub-id pub-id-type="pmid">20697155</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhen</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>T</given-names></name></person-group><article-title>Current developments of macrophage migration inhibitory factor (MIF) inhibitors</article-title><source>Drug Discov Today</source><year>2013</year><volume>18</volume><issue>11&#x02013;12</issue><fpage>592</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2012.12.013</pub-id><?supplied-pmid 23466524?><pub-id pub-id-type="pmid">23466524</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubal</surname><given-names>DB</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Rau</surname><given-names>SW</given-names></name><name><surname>Shughrue</surname><given-names>PJ</given-names></name><name><surname>Merchenthaler</surname><given-names>I</given-names></name><name><surname>Kindy</surname><given-names>MS</given-names></name><name><surname>Wise</surname><given-names>PM</given-names></name></person-group><article-title>Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>4</issue><fpage>1952</fpage><lpage>1957</lpage><?supplied-pmid 11172057?><pub-id pub-id-type="pmid">11172057</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karas</surname><given-names>RH</given-names></name><name><surname>Hodgin</surname><given-names>JB</given-names></name><name><surname>Kwoun</surname><given-names>M</given-names></name><name><surname>Krege</surname><given-names>JH</given-names></name><name><surname>Aronovitz</surname><given-names>M</given-names></name><name><surname>Mackey</surname><given-names>W</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name><name><surname>Smithies</surname><given-names>O</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name></person-group><article-title>Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><issue>26</issue><fpage>15133</fpage><lpage>15136</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.26.15133</pub-id><?supplied-pmid 10611350?><pub-id pub-id-type="pmid">10611350</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macleod</surname><given-names>MR</given-names></name><name><surname>Johansson</surname><given-names>IM</given-names></name><name><surname>Soderstrom</surname><given-names>I</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Gido</surname><given-names>G</given-names></name><name><surname>Wieloch</surname><given-names>T</given-names></name><name><surname>Seckl</surname><given-names>JR</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name></person-group><article-title>Mineralocorticoid receptor expression and increased survival following neuronal injury</article-title><source>Eur J Neurosci</source><year>2003</year><volume>17</volume><issue>8</issue><fpage>1549</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.2003.02587.x</pub-id><?supplied-pmid 12752372?><pub-id pub-id-type="pmid">12752372</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RK</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name></person-group><article-title>Cartilage oligomeric matrix protein (COMP) levels in digital sheath synovial fluid and serum with tendon injury</article-title><source>Equine Vet J</source><year>2000</year><volume>32</volume><issue>1</issue><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.2746/042516400777612053</pub-id><?supplied-pmid 10661386?><pub-id pub-id-type="pmid">10661386</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posey</surname><given-names>KL</given-names></name><name><surname>Hecht</surname><given-names>JT</given-names></name></person-group><article-title>The role of cartilage oligomeric matrix protein (COMP) in skeletal disease</article-title><source>Curr Drug Targets</source><year>2008</year><volume>9</volume><issue>10</issue><fpage>869</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.2174/138945008785909293</pub-id><?supplied-pmid 18855621?><pub-id pub-id-type="pmid">18855621</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>SL</given-names></name><name><surname>Jiao</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>CX</given-names></name><name><surname>Fu</surname><given-names>JM</given-names></name></person-group><article-title>Study on effect of total alkaloids of <italic>Macleaya cordata</italic> to animal&#x02019;s transplanted tumor</article-title><source>Shanxi Onco Med</source><year>2000</year><volume>8</volume><issue>3</issue><fpage>174</fpage><lpage>175</lpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hohenwarter</surname><given-names>O</given-names></name><name><surname>Strutzenberger</surname><given-names>K</given-names></name><name><surname>Katinger</surname><given-names>H</given-names></name><name><surname>Liepins</surname><given-names>A</given-names></name><name><surname>Nowicky</surname><given-names>JW</given-names></name></person-group><article-title>Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain</article-title><source>Drugs Exp Clin Res</source><year>1992</year><volume>18</volume><fpage>S1</fpage><lpage>S4</lpage></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname><given-names>N</given-names></name><name><surname>Plasswilm</surname><given-names>L</given-names></name><name><surname>Bamberg</surname><given-names>M</given-names></name><name><surname>Rodemann</surname><given-names>HP</given-names></name></person-group><article-title>Ukrain, an alkaloid thiophosphoric acid derivative of <italic>Chelidonium majus</italic> L. protects human fibroblasts but not human tumour cells in vitro against ionizing radiation</article-title><source>Int J Radiat Biol</source><year>2002</year><volume>78</volume><issue>1</issue><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1080/09553000110089991</pub-id><?supplied-pmid 11747550?><pub-id pub-id-type="pmid">11747550</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name></person-group><article-title>Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-kappaB and ERK signaling pathways</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>430</volume><issue>3</issue><fpage>951</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.12.051</pub-id><?supplied-pmid 23261473?><pub-id pub-id-type="pmid">23261473</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>KM</given-names></name><name><surname>Das</surname><given-names>M</given-names></name></person-group><article-title>Skin tumor promotion by argemone oil/alkaloid in mice: evidence for enhanced cell proliferation, ornithine decarboxylase, cyclooxygenase-2 and activation of MAPK/NF-kappaB pathway</article-title><source>Food Chem Toxicol</source><year>2010</year><volume>48</volume><issue>1</issue><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2009.09.029</pub-id><?supplied-pmid 19796664?><pub-id pub-id-type="pmid">19796664</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Jung</surname><given-names>WK</given-names></name><name><surname>Jeong</surname><given-names>MH</given-names></name><name><surname>Yoon</surname><given-names>TR</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name></person-group><article-title>Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway</article-title><source>Int J Toxicol</source><year>2012</year><volume>31</volume><issue>1</issue><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1177/1091581811423845</pub-id><?supplied-pmid 22215411?><pub-id pub-id-type="pmid">22215411</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>WY</given-names></name><name><surname>Kim</surname><given-names>GY</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name></person-group><article-title>Sanguinarine, a benzophenanthridine alkaloid, induces apoptosis in MDA-MB-231 human breast carcinoma cells through a reactive oxygen species-mediated mitochondrial pathway</article-title><source>Chemotherapy</source><year>2008</year><volume>54</volume><issue>4</issue><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1159/000149719</pub-id><?supplied-pmid 18667818?><pub-id pub-id-type="pmid">18667818</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrba</surname><given-names>J</given-names></name><name><surname>Orolinova</surname><given-names>E</given-names></name><name><surname>Ulrichova</surname><given-names>J</given-names></name></person-group><article-title>Induction of heme oxygenase-1 by <italic>Macleaya cordata</italic> extract and its constituent sanguinarine in RAW264.7 cells</article-title><source>Fitoterapia</source><year>2012</year><volume>83</volume><issue>2</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2011.11.022</pub-id><?supplied-pmid 22166397?><pub-id pub-id-type="pmid">22166397</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basini</surname><given-names>G</given-names></name><name><surname>Santini</surname><given-names>SE</given-names></name><name><surname>Bussolati</surname><given-names>S</given-names></name><name><surname>Grasselli</surname><given-names>F</given-names></name></person-group><article-title>Sanguinarine inhibits VEGF-induced Akt phosphorylation</article-title><source>Ann N Y Acad Sci</source><year>2007</year><volume>1095</volume><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1196/annals.1397.040</pub-id><?supplied-pmid 17404049?><pub-id pub-id-type="pmid">17404049</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>F</given-names></name><name><surname>Freissmuth</surname><given-names>M</given-names></name><name><surname>Volkel</surname><given-names>D</given-names></name><name><surname>Thiele</surname><given-names>M</given-names></name><name><surname>Douillard</surname><given-names>P</given-names></name><name><surname>Antoine</surname><given-names>G</given-names></name><name><surname>Thurner</surname><given-names>P</given-names></name><name><surname>Ehrlich</surname><given-names>H</given-names></name><name><surname>Schwarz</surname><given-names>HP</given-names></name><name><surname>Scheiflinger</surname><given-names>F</given-names></name></person-group><article-title>Human anti-macrophage migration inhibitory factor (MIF) antibodies inhibit growth of human prostate cancer cells in vitro and in vivo</article-title><source>Mol Cancer Ther</source><year>2013</year><volume>12</volume><issue>7</issue><fpage>1223</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0988</pub-id><?supplied-pmid 23619302?><pub-id pub-id-type="pmid">23619302</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis</article-title><source>Cancer Cell Int</source><year>2013</year><volume>13</volume><issue>1</issue><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1186/1475-2867-13-28</pub-id><?supplied-pmid 23522304?><pub-id pub-id-type="pmid">23522304</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadgaonkar</surname><given-names>R</given-names></name><name><surname>Somnay</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>JG</given-names></name></person-group><article-title>Thrombin induced secretion of macrophage migration inhibitory factor (MIF) and its effect on nuclear signaling in endothelium</article-title><source>J Cell Biochem</source><year>2008</year><volume>105</volume><issue>5</issue><fpage>1279</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1002/jcb.21928</pub-id><?supplied-pmid 18821572?><pub-id pub-id-type="pmid">18821572</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Nishihira</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><name><surname>Ishibashi</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name></person-group><article-title>Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis</article-title><source>Int J Mol Med</source><year>2003</year><volume>12</volume><issue>4</issue><fpage>633</fpage><lpage>641</lpage><?supplied-pmid 12964047?><pub-id pub-id-type="pmid">12964047</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>YC</given-names></name><name><surname>Su</surname><given-names>WH</given-names></name><name><surname>Lei</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Liu</surname><given-names>HS</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name><name><surname>Yeh</surname><given-names>TM</given-names></name></person-group><article-title>Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>5</issue><fpage>e37613</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0037613</pub-id><?supplied-pmid 22629429?><pub-id pub-id-type="pmid">22629429</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>B</given-names></name><name><surname>Jacobson</surname><given-names>JR</given-names></name><name><surname>Siegler</surname><given-names>JH</given-names></name><name><surname>Moitra</surname><given-names>J</given-names></name><name><surname>Blasco</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Unzueta</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Evenoski</surname><given-names>C</given-names></name><name><surname>Al-Sakka</surname><given-names>M</given-names></name></person-group><article-title>Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation</article-title><source>Am J Respir Cell Mol Biol</source><year>2013</year><volume>49</volume><issue>2</issue><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2012-0291OC</pub-id><?supplied-pmid 23526214?><pub-id pub-id-type="pmid">23526214</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>D</given-names></name></person-group><article-title>A new serum biomarker for lung cancer&#x02014;transthyretin</article-title><source>Zhongguo Fei Ai Za Zhi</source><year>2009</year><volume>12</volume><issue>4</issue><fpage>300</fpage><lpage>305</lpage><?supplied-pmid 20719115?><pub-id pub-id-type="pmid">20719115</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Xia</surname><given-names>YL</given-names></name><name><surname>Zhou</surname><given-names>HC</given-names></name><name><surname>Yang</surname><given-names>RB</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>LW</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma</article-title><source>J Cancer Res Clin Oncol</source><year>2013</year><volume>139</volume><issue>7</issue><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1007/s00432-013-1422-4</pub-id><?supplied-pmid 23546595?><pub-id pub-id-type="pmid">23546595</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Aparicio</surname><given-names>C</given-names></name><name><surname>Carnero</surname><given-names>A</given-names></name></person-group><article-title>Pim kinases in cancer: diagnostic, prognostic and treatment opportunities</article-title><source>Biochem Pharmacol</source><year>2013</year><volume>85</volume><issue>5</issue><fpage>629</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2012.09.018</pub-id><?supplied-pmid 23041228?><pub-id pub-id-type="pmid">23041228</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Fukuda</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Matsuzaki</surname><given-names>J</given-names></name><name><surname>Kodama</surname><given-names>H</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><article-title>Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes</article-title><source>Circ Res</source><year>1999</year><volume>84</volume><issue>10</issue><fpage>1127</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1161/01.RES.84.10.1127</pub-id><?supplied-pmid 10347087?><pub-id pub-id-type="pmid">10347087</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pencikova</surname><given-names>K</given-names></name><name><surname>Urbanova</surname><given-names>J</given-names></name><name><surname>Musil</surname><given-names>P</given-names></name><name><surname>Taborska</surname><given-names>E</given-names></name><name><surname>Gregorova</surname><given-names>J</given-names></name></person-group><article-title>Seasonal variation of bioactive alkaloid contents in <italic>Macleaya microcarpa</italic> (Maxim.) Fedde</article-title><source>Molecules</source><year>2011</year><volume>16</volume><issue>4</issue><fpage>3391</fpage><lpage>3401</lpage><pub-id pub-id-type="doi">10.3390/molecules16043391</pub-id><?supplied-pmid 21512447?><pub-id pub-id-type="pmid">21512447</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HH</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>ZL</given-names></name><name><surname>Liu</surname><given-names>ZY</given-names></name></person-group><article-title>Identification of sanguinarine metabolites in pig liver preparations by accurate mass measurements using electrospray ionization hybrid ion trap/time-of-flight mass spectrometry</article-title><source>Rapid Commun Mass Spectrum</source><year>2013</year><volume>27</volume><issue>9</issue><fpage>979</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1002/rcm.6538</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Gou</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Fleck</surname><given-names>C</given-names></name></person-group><article-title>Current progresses of novel natural products and their derivatives/analogs as anti-Alzheimer candidates: an update</article-title><source>Mini Rev Med Chem</source><year>2013</year><volume>13</volume><issue>6</issue><fpage>870</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.2174/1389557511313060009</pub-id><?supplied-pmid 23305400?><pub-id pub-id-type="pmid">23305400</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>S</given-names></name><name><surname>Vaux</surname><given-names>DJ</given-names></name></person-group><article-title>Parkinson&#x02019;s disease, Alzheimer&#x02019;s disease and motor neurone disease: identifying a common mechanism</article-title><source>Neurosci</source><year>2002</year><volume>113</volume><issue>3</issue><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00194-X</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Multitarget-directed benzylideneindanone derivatives: anti-beta-amyloid (Abeta) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer&#x02019;s disease</article-title><source>J Med Chem</source><year>2012</year><volume>55</volume><issue>19</issue><fpage>8483</fpage><lpage>8492</lpage><pub-id pub-id-type="doi">10.1021/jm300978h</pub-id><?supplied-pmid 22978824?><pub-id pub-id-type="pmid">22978824</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMarcaida</surname><given-names>JA</given-names></name><name><surname>Schwid</surname><given-names>SR</given-names></name><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Blindauer</surname><given-names>K</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Shoulson</surname><given-names>I</given-names></name></person-group><article-title>Effects of tyramine administration in Parkinson&#x02019;s disease patients treated with selective MAO-B inhibitor rasagiline</article-title><source>Mov Disord</source><year>2006</year><volume>21</volume><issue>10</issue><fpage>1716</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1002/mds.21048</pub-id><?supplied-pmid 16856145?><pub-id pub-id-type="pmid">16856145</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>PL</given-names></name><name><surname>Clark</surname><given-names>PK</given-names></name><name><surname>Hughes</surname><given-names>SH</given-names></name></person-group><article-title>HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>10</issue><fpage>5885</fpage><lpage>5894</lpage><pub-id pub-id-type="doi">10.1128/JVI.06597-11</pub-id><?supplied-pmid 22438533?><pub-id pub-id-type="pmid">22438533</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klarmann</surname><given-names>GJ</given-names></name><name><surname>Hawkins</surname><given-names>ME</given-names></name><name><surname>Le Grice</surname><given-names>SF</given-names></name></person-group><article-title>Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target</article-title><source>AIDS Rev</source><year>2002</year><volume>4</volume><issue>4</issue><fpage>183</fpage><lpage>194</lpage><?supplied-pmid 12555693?><pub-id pub-id-type="pmid">12555693</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrose</surname><given-names>Z</given-names></name><name><surname>Herman</surname><given-names>BD</given-names></name><name><surname>Sheen</surname><given-names>CW</given-names></name><name><surname>Zelina</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>KL</given-names></name><name><surname>Tachedjian</surname><given-names>G</given-names></name><name><surname>Nissley</surname><given-names>DV</given-names></name><name><surname>Sluis-Cremer</surname><given-names>N</given-names></name></person-group><article-title>The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs</article-title><source>J Virol</source><year>2009</year><volume>83</volume><issue>8</issue><fpage>3826</fpage><lpage>3833</lpage><pub-id pub-id-type="doi">10.1128/JVI.01968-08</pub-id><?supplied-pmid 19193782?><pub-id pub-id-type="pmid">19193782</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadiq</surname><given-names>SK</given-names></name><name><surname>Noe</surname><given-names>F</given-names></name><name><surname>De Fabritiis</surname><given-names>G</given-names></name></person-group><article-title>Kinetic characterization of the critical step in HIV-1 protease maturation</article-title><source>Proc Natl Acad Sci USA</source><year>2012</year><volume>109</volume><issue>50</issue><fpage>20449</fpage><lpage>20454</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210983109</pub-id><?supplied-pmid 23184967?><pub-id pub-id-type="pmid">23184967</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Vickrey</surname><given-names>JF</given-names></name><name><surname>Proteasa</surname><given-names>G</given-names></name><name><surname>Jimenez</surname><given-names>YL</given-names></name><name><surname>Wawrzak</surname><given-names>Z</given-names></name><name><surname>Winters</surname><given-names>MA</given-names></name><name><surname>Merigan</surname><given-names>TC</given-names></name><name><surname>Kovari</surname><given-names>LC</given-names></name></person-group><article-title>&#x0201c;Wide-open&#x0201d; 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target</article-title><source>Structure</source><year>2005</year><volume>13</volume><issue>12</issue><fpage>1887</fpage><lpage>1895</lpage><pub-id pub-id-type="doi">10.1016/j.str.2005.11.005</pub-id><?supplied-pmid 16338417?><pub-id pub-id-type="pmid">16338417</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>IL</given-names></name><name><surname>Mahindroo</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>PH</given-names></name><name><surname>Peng</surname><given-names>YH</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Tsai</surname><given-names>KC</given-names></name><name><surname>Hsieh</surname><given-names>HP</given-names></name><name><surname>Chao</surname><given-names>YS</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name></person-group><article-title>Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease</article-title><source>J Med Chem</source><year>2006</year><volume>49</volume><issue>17</issue><fpage>5154</fpage><lpage>5161</lpage><pub-id pub-id-type="doi">10.1021/jm060207o</pub-id><?supplied-pmid 16913704?><pub-id pub-id-type="pmid">16913704</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>BA</given-names></name><name><surname>Krishnan</surname><given-names>R</given-names></name><name><surname>Khadtare</surname><given-names>N</given-names></name><name><surname>Gurukumar</surname><given-names>KR</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Bhatt</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Dana</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Design and synthesis of &#x0029f;- and <sc>d</sc>-phenylalanine derived rhodanines with novel C5-arylidenes as inhibitors of HCV NS5B polymerase</article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><issue>11</issue><fpage>3262</fpage><lpage>3671</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.03.041</pub-id><?supplied-pmid 23598249?><pub-id pub-id-type="pmid">23598249</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varshney</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>PK</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>A review on an update of NS5B polymerase hepatitis C virus inhibitors</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2012</year><volume>16</volume><issue>5</issue><fpage>667</fpage><lpage>671</lpage><?supplied-pmid 22774409?><pub-id pub-id-type="pmid">22774409</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>DB</given-names></name><name><surname>Basarab</surname><given-names>GS</given-names></name><name><surname>Steffens</surname><given-names>JJ</given-names></name><name><surname>Schwartz</surname><given-names>RS</given-names></name><name><surname>Doughty</surname><given-names>JG</given-names></name></person-group><article-title>Tight binding inhibitors of scytalonedehydratase: effects of site-directed mutations</article-title><source>Biochemistry-Us</source><year>2000</year><volume>39</volume><issue>29</issue><fpage>8593</fpage><lpage>8602</lpage><pub-id pub-id-type="doi">10.1021/bi000467m</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stammers</surname><given-names>DK</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Leslie</surname><given-names>K</given-names></name><name><surname>Nichols</surname><given-names>CE</given-names></name><name><surname>Lamb</surname><given-names>HK</given-names></name><name><surname>Cocklin</surname><given-names>S</given-names></name><name><surname>Dodds</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>AR</given-names></name></person-group><article-title>The structure of the negative transcriptional regulator NmrA reveals a structural superfamily which includes the short-chain dehydrogenase/reductases</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><issue>23</issue><fpage>6619</fpage><lpage>6626</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.23.6619</pub-id><?supplied-pmid 11726498?><pub-id pub-id-type="pmid">11726498</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Hume</surname><given-names>SL</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Lamb</surname><given-names>HK</given-names></name><name><surname>Hawkins</surname><given-names>AR</given-names></name></person-group><article-title>The transcription repressor NmrA is subject to proteolysis by three <italic>Aspergillus nidulans</italic> proteases</article-title><source>Protein Sci</source><year>2010</year><volume>19</volume><issue>7</issue><fpage>1405</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1002/pro.421</pub-id><?supplied-pmid 20506376?><pub-id pub-id-type="pmid">20506376</pub-id></element-citation></ref></ref-list></back></article>